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Scope of the thesis
 
10
This thesis describes structural studies of two proteins from two biological 
systems. The first part (Part I) consists of chapters 1, 2 and 3, while the second 
part (Part II) consists of chapters 4 and 5 and deals with the lytic transglycosylase 
MltF from Escherichia coli.
The first part of the thesis discusses the mechanism of multidrug 
recognition by the transcriptional regulator LmrR from Lactococcus lactis. LmrR 
regulates the expression of the multidrug transporter LmrCD, which belongs 
to ABC superfamily and is primarily responsible for the multidrug phenotype 
of L. lactis. By binding various ligands similar to its cognate transporter, 
LmrR undergoes a structural change facilitating the upregulation of LmrCD. 
Understanding the features of multidrug recognition will allow further 
expansion of the multidrug recognition principles, as this is the first example 
of a transcriptional regulator that governs a multidrug ABC transporter. 
The second part of the thesis consists of chapters 4 and 5 and deals with 
the lytic transglycosylase MltF from Escherichia coli. Lytic transglycosylases 
(LTs) are enzymes involved in peptidoglycan (PG) metabolism. They catalyze 
two reactions on PG. One is the cleavage of the β-1,4-glycosidic bond, similar 
to lysozyme, the other is the subsequent intra-residue transglucosylation 
reaction, in which a 1,6-glycosidic bond is formed, thereby producing GlcNAc-
anhydro-muropeptides. These end-products are the hallmark of LTs. In E. 
coli different types of LTs are present, but specific roles of them in the E. coli 
metabolism remain unclear. These enzymes differ from each other by having 
additional domains for which the function is often unknown. MltF differs from 
other LTs by having an N-terminal periplasmic binding domain (MltF-NTD) and 
a common C-terminal lysozyme like fold. Structural investigations on MltF may 
allow a better understanding of MltF-NTD.
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Chapter 1 - Introduction
Why is there an urgent need to tackle antibiotic resistance in pathogenic 
microbes? How do microbes gain resistance to the available antibiotics? 
What are the principles of MD recognition? Why do we need to study MD 
recognition? These questions are addressed in this chapter by describing 
resistance mechanisms, multidrug transporters, and several reasons for the 
need of MD-related transcriptional regulators in pathogenic microbes. A short 
overview of the canonical and non-canonical types of multidrug recognition 
is presented to understand how LmrR multidrug recognition differs from the 
canonical recognition, which is the main subject of this thesis.
Chapter 2 - Structure of the transcriptional regulator LmrR and its 
mechanism of multidrug recognition
MD recognition principles of the members of PadR family are not known. Chapter 
2 describes the structural analysis of LmrR. Multidrug binding principles are 
derived by comparison of structures between apo and drug bound forms of 
LmrR. LmrR bound to Hoechst 33342 and daunomycin emphasizes the role of 
a single drug binding site that can accommodate structurally different ligands. 
Primarily, dimer-related tryptophan residues play a dominant role in aspecific 
binding, in which the indole rings sandwich the planar ring system of different 
compounds. The observed drug binding features in LmrR differs considerably 
from the current views of MD recognition.
Chapter 3 - Multidrug resistance regulator LmrR uses a single site to bind 
structurally diverse compounds
Chapter 3 describes additional structures of LmrR in complex with two 
chemically different ligands, ethidium and riboflavin. These structures 
emphasize the role of a single ligand-binding site at the dimer interface for 
MD recognition. 
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Chapter 4 - Purification, crystallization and preliminary X-ray diffraction 
analysis of the lytic transglycosylase MltF from Escherichia coli
In this chapter the purification, crystallization and preliminary X-ray analysis of 
two soluble, C-terminally His6-tagged forms of MltF lacking residues 1-22 are 
described. One form of the protein contains both domains (sMltF), whilst the 
other contains only the N-terminal domain (sMltF-NTD).
Chapter 5 - Crystal structure of the SBP-like N-terminal domain of 
Escherichia coli lytic transglycosylase MltF 
Chapter 5 describes structural features of MltF-NTD. We present the structure 
and compare it with structural homologs and highlight that the ligand-binding 







Rise and fall of antibiotics efficacy
In 1929, Alexander Fleming observed that a mold of contaminating Penicillium 
notatum on a Staphylococcus agar plate prevented the growth of bacteria. This 
finding marked the beginning of the development of antibiotics to combat 
infectious diseases, and it was one of the most valuable discoveries in the 20th 
century. Nevertheless, the use of natural resources for the treatment of various 
infections can be dated back to over thousand years ago 1, most often referred 
to as “grandma recipes”, some of which are still in practice. Fleming’s discovery 
led to the identification of penicillin as the first antibiotic. It was considered a 
wonder drug because it appeared to be able to combat all kinds of pathogenic 
organisms. The discovery of penicillin was followed later by a rapid discovery 
of other new antibiotics, not to have a library of different entities a priori, but 
as weapons to reduce the rise of deadly infections 2. However, pathogens that 
were once effectively treated with a particular antibiotic, have been gaining 
alterations in their physiological systems, enabling them to neutralize the 
toxicity of the antibiotics. This phenomenon is called resistance. Resistance 
can be transferred across different taxonomic groups by mobile genetic 
elements, like naked DNA or transposons, plasmids, and bacteriophages 3. In 
the absence of mobile elements, step-wise mutations in chromosomes can 
also lead to resistance in bacteria 4; 5. This process was shown to be responsible 
for the emergence of resistance against penicillin and tetracycline in e.g. 
Neisseria gonorrhoeae. Because of improper use of antibiotics and continuous 
exposure to new generations of antibiotics and because resistance can easily 
be transferred, microbes have developed, in a relatively short period of time, 
resistance to various classes of antibiotics 2; 6; 7. Moreover, they developed 
resistance to multiple antibiotics, leading to the emergence of a multiple 
antibiotic resistance (mar) phenotype. Notable examples in this case are strains 
of Mycobacterium tuberculosis, Enterococcus faecium, Enterobacter cloacae, 
Klebsiella pneumoniae, Staphylococcus aureus, Acinetobacter baumannii and 
Pseudomonas aeruginosa 8; 9. Rather than using a single antibiotic, mar requires 
the use of several antibiotics to treat a specific infection. Such a treatment, 
unfortunately, at the same time accelerates the evolution of new types of 
resistant strains 10; 11. As a result, resistant strains are rising at a rate that is not 




Mechanisms of antibiotic resistance 
The biological route by which microbes demonstrate resistance varies and can 
be divided into different categories: (i) direct action against the antibiotics; 
(ii) the alteration of the antibiotic target inside the cellular milieu, making 
the drug unable to inhibit a vital function, and (iii) drug induced oxidative 
stress. An example of a direct action of microbes against an antibiotic is the 
expression of enzymes, such as β-lactamases, which destroy penicillins and 
cephalosporins 12, and of membrane-bound pumps that actively excrete the 
antibiotics from the cell. Alteration of the antibiotic target inside the cellular 
milieu is exemplified by the synthesis of ribosomal protection proteins (RPP), 
which induce conformational changes in the ribosomes 13. Ribosomes are the 
target of the antibiotic tetracycline, and by changing the conformation of 
the ribosome microbes have developed resistance against this antibiotic. In 
the third category, the drug itself can act as a mutagen and give rise to drug 
resistant strains. Certain antibiotics like β-lactams and quinolones induce the 
formation of reactive oxygen species (ROS), which can damage the DNA, and 
activate the error-prone SOS response. Thus ROS in conjunction with SOS leads 
to emergence of mutations, which results in the emergence of a resistant strain 
14;15. Details of resistance mechanisms have been reviewed by Alekshun & Levy 
16. Except for the efflux pumps, the resistance mechanisms described above 
are limited to a certain class of antibiotics. In contrast, efflux pumps have the 
ability to extrude a broad spectrum of chemically distinct cytotoxic molecules 
17. Organisms which possess these pumps, be it prokaryotes or eukaryotes, 
often show a multidrug resistance (MDR) phenotype 18; 19; 20. 
Multidrug efflux pumps in bacteria
All efflux pumps/transporters reside in the cell membrane and they can be 
divided into two families based on bioenergetic and structural features: (i) 
primary transporters which use ATP as their source of energy, also known as 
ATP–binding cassette (ABC) transporters (e.g. sav1866 from Staphylococcus 
aureus and the mammalian P-glycoprotein) and (ii) secondary transporters 
which utilize the proton (or sodium) gradient as a source of energy. On the 
basis of their structural organization and substrate specificity, secondary 




families: (i) the multidrug and toxic compound extrusion (MATE) family (e.g. 
NorM from Erwinia amylovora); (ii) the major facilitator superfamily (MFS; 
e.g. EmrD from E. coli); (iii) the small multidrug resistance (SMR) family 21 (e.g. 
EmrE from E. coli) and (iv) the resistance nodulation division (RND) family 
(e.g. AcrB from E. coli) 22. Structures of the multidrug transporters with bound 
drugs are limited. The only structures of MDR pumps with bound substrates 
are those of P-glycoprotein bound to cyclic peptide inhibitors (4.4 Å) 23, AcrB 
with minocycline and doxorubicin at 3.1 and 3.3 Å resolution 24 and the 7.0 
Å structure of the complex of EmrE with TPP+ (tetraphenylphosphonium) 25. 
These complexes, though limited in number and resolution, indicate the 
importance of a flexible voluminous drug-binding pocket containing mainly 
aliphatic and aromatic hydrophobic amino acids for multi drug recognition. 
Despite their role in drug resistance, efflux pumps usually have a basal 
level of expression because they also perform a physiological role to provide 
protection for the microbes in their ecological niche. For instance, enteric 
bacteria (which reside in the gastrointestinal tract of humans and animals) 
use the AcrAB pump to survive in the hydrophobic environment constituted 
by bile salts and fatty acids26. The multidrug transporter Blt of Bacillus subtilis 
is normally co-induced with enzymes involved in spermidine/spermine 
metabolism and its normal function is a spermidine transporter 27; 28. The 
chemical character of several toxic compounds designed against pathogens 
is similar to the compounds normally encountered by bacteria in their natural 
environment. For example, many natural and synthetic cytotoxic compounds 
contain planar aromatic groups, have a lipophilic nature and are often weakly 
cationic. The basal level of expression and broad substrate specificity of 
MDR efflux pumps ensure that a bacterial cell is always ready to defend itself 
against environmental toxins29. However, the basal expression level of MDR 
pumps is not sufficient to support resistance to toxic compounds at higher 
concentrations and, therefore, in several cases, efflux pumps are upregulated. 
The upregulation is achieved by sensory molecules residing in the cell that are 
referred to as “transcriptional regulators”, which control the expression of their 




Fine tuning of the expression of MDR pumps
Considering their broad substrate specificity, MDR pumps can be potentially 
dangerous to the cell. For example, constitutive expression of the tetracycline 
resistance pumps TetA(B) and TetA(C) in gram-negative bacteria has an impact 
on the fitness of the cells 30; 31. Since TetA(B) utilizes the proton motive force 
to extrude the drugs, overexpression of TetA(B) in the absence of target will 
result in leakage of cations, which leads to loss of membrane potential and, 
eventually, to cell death 32; 33. Thus, it is important that the expression levels of 
MDR pumps are tightly tuned to intracelllular drug concentrations, to avoid 
unnecessarily high, and lethal, MDR activity.
In bacteria, both transcriptional activators and repressors regulate the 
expression of MDR efflux pumps. Transcriptional repressors of MDR pumps 
include members of the TetR, MarR and LacI families, whilst transcriptional 
activators belong to the MerR, AraC or LysR families (Table 1). To perform their 
regulatory activities, many transcriptional regulators contain a DNA-binding 
domain and a ligand-binding domain. The ligand-binding domains of these 
regulators often bind the same spectrum of ligands (antibiotics or toxic 
compounds) as the transcriptionally controlled MDR pumps. Drug-induced 
upregulation of an MDR pump results from a drug-coupled conformational 
change in the DNA-binding domains of the transcriptional regulator, either 
causing a weakening (in case of a repressor) or strengthening (in case of an 
activator) of the DNA binding affinity. For instance, upregulation of the Bmr 
transporter in Bacillus subtilis, which is controlled by the regulator BmrR, 
occurs when ligand-bound BmrR binds the promoter region of the bmr gene. 
Here, BmrR acts as an activator 34. In contrast, ligand-induced conformational 
changes in transcriptional repressors such as QacR in Staphylococcus aureus 35 
and EmrR in E. coli 36 prevent the regulators to bind to their target promoters, 
leading to the upregulation of the upstream-located MDR transporter genes. 
All the MDR transcriptional regulators described so far (including those in Table 




Structural variations in MDR transcriptional regulators 
Based on similarities of their DNA binding domains, transcriptional regulators 
of MDR pumps have been grouped into five families: AraC, MerR, TetR, MarR 
and PadR-like. All the regulators from these families have a helix-turn-helix 
(HTH) structural motif to bind to DNA. The two motifs in the AraC family are 
present in one single polypeptide chain 51. In contrast, the two HTH motifs in 
the TetR family, are obtained through dimerization of two protomers harboring 
a single HTH motif each 52. In MarR, MerR and PadR-like family members the 
DNA binding domain contains an extension to the HTH motif in the form of 
a “β-wing” (together referred to as a winged-HTH motif ). In MerR, the wing is 
formed by three antiparallel β-strands, whereas the wing in the MarR and PadR 
family members consists of a two-stranded β-sheet 53. In all these winged-
HTH motif containing proteins, the wing is located at the C-terminus of the 
DNA binding domain and positioned in such a way as to provide additional 
interactions with the DNA 53. 
In contrast to their DNA binding domains, considerable differences 
are observed for the ligand-binding domains of MDR-related transcriptional 
regulators. This is somewhat surprising, considering that many regulators 
bind chemically similar   drugs, but highlights the importance of studying 
the principles of multidrug specificity. Furthermore, MDR transcriptional 
regulators are more feasible for structural and drug binding studies compared 
to membrane-bound cognate MDR pumps as they can be easily expressed and 


















































































































































































































































































































































































































































































































































































































































As this thesis is concerned with the multidrug binding properties of the 
transcriptional regulator LmrR from the PadR-like family, understanding these 
properties for the well studied transcriptional regulators like QacR and BmrR, 
which belong to different families, helps in appreciating the uniqueness of the 
binding pockets that confer multidrug specificity. Therefore, in the following 
sections, structural views are presented on the multidrug binding properties 
of these two transcriptional regulators. 
the canonical view of multidrug recognition:  
the multifaceted ligand-binding site of QacR of the tetR family
The Staphylococcus aureus MDR pump QacA, which was the first MDR pump 
protein reported in bacteria56, confers resistance to monovalent and bivalent 
cationic lipophilic disinfectants and antiseptics such as quaternary ammonium 
compounds (QACs). The transcriptional regulator QacR regulates the expression 
of the qacA gene56. QacR was classified in the TetR family on the basis of the 
similarity of its N-terminal HTH motif to that of TetR57. The ligand/drug binding 
region is located at the junction between the dimerization interface of two 
individual monomers and the DNA binding domain (Figure 1A). QacR has a 
broad substrate specificity, which ranges from various quaternary ammonium 
compounds to disinfectants and antibiotics that represent almost all the 
substrates exported by the QacA pump. Several structures of QacR have been 
obtained, bound with different ligands, such as ethidium, rhodamine 6G, 
berberine, dequalinium, crystal violet and proflavin 45; 58; 59. These ligands, which 
have a volume of ~300-400 Å3, bind in a large voluminous drug-binding pocket 
of ~1100 Å3. Their binding is not restricted to a common location in the drug-
binding pocket, but is rather segregated into small mini-pockets (Figure 1B). 
Because of these distinct overlapping mini-pockets, the drug-binding pocket 
in QacR provides extensive and different interaction surfaces for chemically 
different ligands (Figure 1B). 
The drug-protein interactions are dominated by interactions of the drugs 
with the side chains of aromatic residues (Phe, Tyr, and Trp). Aromatic residues 
contribute to multi-specific (alternatively referred to as promiscuous) drug 
binding due to their non-specific π-interactions, such as π-π, π-hydrophobic, 
and π-cationic, with the drugs. The binding of structurally different ligands 




flexibility of these side chains, allowing them to adopt ligand-dependent 
rotameric states. Due to their distribution in the voluminous drug-binding 
pocket and as well as due to their non-specific interactions with the planar 
ring system of the ligands, aromatic residues also facilitate binding of more 
than one drug simultaneously44. In addition to the aromatic side chains, 
H-bonding and electrostatic interactions also contribute to the plasticity in 
MD recognition. In QacR, at least three Glu and two Asp residues adopt drug-
dependent rotameric states for optimal H-bonding interactions. 
In the TtgR regulator, which belongs to same family as QacR, the 
binding pocket (ca. 1500 Å3) is larger than that of QacR; this pocket facilitates 
the binding of several different, mostly plant-derived drugs with the help of 
hydrophobic residues 47. However, in sharp contrast to QacR, the ligand-binding 
pocket in TtgR is dominated by aliphatic hydrophobic residues and contains 
only a single aromatic residue (six in QacR). Aliphatic hydrophobic residues are 
also well suited for MD recognition and are well known for their involvement 
Figure 1. Canonical view of MD recognition in QacR. A) Cartoon representation of the QacR 
dimer from S. aureus (PDB entry 1JTY). The two subunits are represented in blue and orange. 
B) top-view of the drug binding site showing various drugs which interact with different areas 
of the large drug-binding cavity. Chemically different drugs are represented in sticks. Ethidium 
bromide (Et), dequalinium (Deq), rhodamine 6G (R6G), crystal violet (Cv), berberine (Ber), 




in multi-specific ligand recognition like in antigen-antibody interactions60; 61, 
odorant binding protein62 and the PXR transcriptional regulator63. 
Several of the drug complexes of QacR and TtgR underscore the 
importance of an adaptable voluminous binding pocket and the hydrophobic 
character in MD recognition. These features are also shared in MD related 
pumps like AcrB 64 and Pgp 23 and form the basis of the canonical MD recognition 
features. In several other cases, like LmrA from Lactococcus lactis and MsbA from 
E. coli, ligand-protein interaction studies show the same canonical features 65. 
Promiscuous drug recognition is not only unique to MD related proteins, but 
is also utilized by enzymes involved in drug metabolism and disposition66. 
For example, in the drug-metabolizing enzyme cytochrome P450 the ligand-
binding site is similar to that of QacR: it is a voluminous ligand-binding site 
with aromatic residues that can bind more than one drug simultaneously 67.
A non-canonical view of multi-drug recognition in BmrR of the MerR 
family
The transcriptional activator BmrR regulates the expression of the MDR 
transporter Bmr in Bacillus subtilis 34. Like QacR, BmrR is functionally active 
as a homodimer. Within each monomer, the ligand binding domain and the 
DNA binding domain are far away from each other (Figure 2A). However, in 
the dimeric form, the ligand binding domain of one monomer interacts with 
the DNA binding domain of the other, facilitating the drug induced activation 
of the bmr promoter 39. Because of this structural organization, there are two 
identical drug-binding sites in the BmrR dimer (Figure 2A). The drug-binding 
site of BmrR (ca. 650 Å3) is much smaller than that of QacR (ca. 1100Å3). It lacks 
distinct multiple sites and an adaptable binding pocket (Figure 2B), which 
are the core requirements for the canonical drug binding site as described 
above. In BmrR, the drug-binding site is rather rigid and offers a platform for 
chemically unrelated ligands by retaining key MD-binding elements: aromatic 
and aliphatic residues. In several of the BmrR drug-bound complexes 37, 
these residues form a conformationally rigid ring-like scaffold for binding the 
aromatic ring systems common to the various ligands. Another subsite, which 
is more solvent exposed and contains hydrogen-bonding elements, provides a 




Figure 2. BmrR model and non-canonical MD recognition. A) Cartoon representation of the 
structure of BmrR from B. subtilis in the presence of DNA (PDB entry 1EXJ). The two equivalent 
ligand-binding sites (dyad-related) contain an overlay of several ligands (shown as sticks 
in yellow and pink). B) Close-up side view of the drug-binding site. Various drugs bound at a 
common surface are depicted as sticks. 
transcriptional regulators of the PadR family
Microorganisms living in a plant-soil ecosystem survive phenolic acid stress by 
the expression of a phenolic acid decarboxylase gene (padA gene). Phenolic 
acids are abundant in plant cell walls and vacuoles 68. They are released as free 
acids such as p-coumaric, ferulic and caffeic acids by the action of hemicellulases 
produced by fungi and bacteria. These antimicrobial compounds are converted 
into less-toxic derivatives by phenolic acid decarboxylase (Pad) encoded by 
the inducible padA gene69; 70. The transcriptional regulator PadR negatively 
regulates the expression of the padA gene. PadR was the founding member 
of a new class of transcriptional regulators, the PadR family (Pfam PF03551). 
The PadR family now includes a large and diverse group of proteins, of which 
only a few have been characterized. Among these proteins, the transcriptional 
activator AphA (31% identity to PadR) initiates the virulence cascade in Vibrio 
cholerae 71; 72, without apparently playing a role in the regulation of Pad 73. LadR 
is a regulator that is widely conserved in firmicutes and related organisms; 
it regulates the expression of the multidrug efflux pump MdrL 74. This efflux 
pump is known to extrude multiple substrates, which include ethidium, 
macrolides, cefotaxime and heavy metals 75. Other members of the PadR family 
are LstR, which is required for effective thermal resistance 76, and LmrR from 




ABC transporter 48; 77. Based on the length of their ORFs, padR-related genes 
have been classified into two distinct subfamilies, subfamilies I and II, which 
encode proteins of ~176 and ~110 amino acids, respectively74. PadR, LadR 
and AphA belong to the PadR subfamily I and LmrR belongs to subfamily II. 
Crystal structures of two PadR-like proteins, AphA 78 and Pex 79, revealed the 
presence of an N-terminal wHTH DNA binding motif, which is highly similar to 
that found in the MarR family42. However, the C-terminal dimerization domains 
of AphA and Pex are highly divergent in PadR as well as from the MarR family 
(top-view in Figure 3). 
LmrR from Lactococcus lactis
The lmrR (lactococcal multidrug resistance regulator) gene is located upstream 
of the lmrCD genes. LmrR, the expression product of the lmrR gene, negatively 
regulates the expression of the ABC transporter LmrCD, a major determinant 
of the MDR phenotype of Lactococcus lactis 80. In non-induced conditions, 
LmrR binds to the promoter of lmrCD, thereby repressing its expression. In the 
presence of inducers, like the cellular toxic compounds daunomycin, ethidium, 
Hoechst 33342, and the fluorescence dye BCECF-AM (5-carboxyfluorescein, 
diacetoxymethyl ester), repression of lmrCD is relieved resulting in increased 
Figure 3. Variations in the dimerization domains of different PadR family members. 
Cartoon representation of AphA (PDB entry 1YG2), Pex (PDB entry 2E1N) and LmrR (PDB entry 





production of the membrane-bound efflux pump LmrCD. Possibly, LmrR 
undergoes a conformational change upon drug binding, which prohibits 
it from binding to the promoter of the lmrCD genes. At the same time, in L. 
lactis MDR strains, it has been observed that expression of LmrR itself is also 
enhanced81. Thus LmrR plays a dual regulatory role by binding, though in a 
different stoichiometry, to the control regions of both the lmrR and lmrCD 
genes82. LmrR is bound to its own control region in a high copy number fashion, 
whereas two copies of LmrR dimer are bound to the lmrCD control region. This 
might ensure a demand-based expression of LmrCD. For example, at elevated 
levels of toxicity both the regulator and the functional genes could be induced 
and co-transcribed from a polycistronic messenger, and at the same time a 
single transcript of LmrCD could be transcribed leading to the higher-level 
expression of LmrCD. 
Crystal structures of apo LmrR, and complexes of LmrR with bound 
Hoechst 33342 and daunomycin have been solved at 2.0 Å and 2.2 Å, 
respectively 48. Remarkably, although LmrR retains an N-terminal helix-turn-
helix motif for binding to DNA, its C-terminal ligand(s) binding domain has 
a unique architecture that deviates from the well studied QacR and BmrR 
regulators. The dimer contains a large central pore at the subunit interface that 
is symmetric with equal contributions from both monomers. The planar ring 
system of the two toxic compounds is wedged in between the W96 and W96’ 
side chains forming aromatic stacking interactions with each of the two indole 
systems. There are no hydrogen bonding interactions between the drug(s) and 
LmrR. 
Concluding Remarks
Pathogenic microorganisms have evolved over time to survive the continuous 
onslaught of antibiotics. Due to the abuse of antibiotics, several microbes, 
which once were sensitive, are transforming into ‘superbugs’ by becoming 
resistant to almost all available antibiotics. Resistance comes in different flavors 
and is problematic to investigate. This is caused, firstly, by the different types 
of resistance mechanisms, secondly because pathogenic microorganisms 
employ a combination of resistance mechanisms to ensure their safety from 
a plethora of antibiotics, and, finally, because these mechanisms can be 




the production of new antibiotics is to understand the mechanisms by which 
pathogenic microbes attain resistance. For such an approach multidrug efflux 
pumps are of significant importance because of their ability to recognize the 
chemically different toxic compounds by which microbes attain multidrug 
resistance. However, structural studies on efflux pumps are hampered by the 
difficulties in purifying and crystallizing membrane proteins. On the other 
hand, MDR related regulatory proteins are soluble, relatively easy to produce 
in the amounts required for structural studies and it is often easy to obtain 
diffracting crystals. Structural studies on regulatory proteins are beginning 
to provide features for multidrug recognition. For example, numerous drug-
bound complexes of QacR and TtgR display the canonical basis of multi-
drug recognition, which is also shared by MDR-related pumps like Pgp and 
AcrB. In addition to this model, BmrR drug bound complexes presented a 
non-canonical model of drug recognition. These studies now indicate that 
multidrug recognition can be varied. Our current knowledge about different 
MD recognition mechanisms is limited. There is a further need for additional 
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LmrR is a PadR-related transcriptional repressor that regulates the production 
of LmrCD, a major multidrug ABC transporter in Lactococcus lactis. 
Transcriptional regulation is presumed to follow a drug-sensitive induction 
mechanism involving the direct binding of transporter ligands to LmrR. Here 
we present crystal structures of LmrR in the apo state and in two drug-bound 
states, complexed with Hoechst 33342 and daunomycin, respectively. LmrR 
shows a common topology containing a typical β-winged helix-turn-helix 
domain with an additional C-terminal helix involved in dimerization. Its dimeric 
organization is highly unusual with a flat-shaped hydrophobic pore at the 
dimer centre serving as a multi-drug binding site. The drugs bind in a similar 
fashion with their aromatic rings sandwiched in between the indole groups of 
two dimer-related tryptophan residues. Multi-drug recognition is facilitated by 
conformational plasticity and the absence of drug-specific hydrogen bonds. 
Combined analyses using site-directed mutagenesis, fluorescence-based 
drug binding and protein-DNA gel shift assays reveal an allosteric coupling 
between the multidrug and DNA binding sites of LmrR that likely plays a role 
in the induction mechanism. 




Multidrug resistance (MDR) is frequently caused by the action of specialized 
membrane-bound pumps that possess or have acquired the ability to extrude 
a wide variety of chemically and structurally different compounds from the 
cell (Higgins, 2007; Saier et al, 1998). The molecular mechanisms of substrate 
recognition by these multi-drug transporters are poorly understood, mainly 
because the proteins involved are very recalcitrant towards crystallization, 
a prerequisite for a detailed structural analysis by X-ray crystallography. 
Instead, general features explaining multi-drug binding specificity have been 
derived from structural studies of the transcriptional regulators of multi-drug 
transporters, which are soluble proteins and often bind many of the same 
drugs that are substrates of the pumps (Alguel, 2007; Heldwein & Brennan, 
2001; Higgins, 2007; Schumacher et al, 2001; Zheleznova et al, 1999). 
LmrR is a recently identified transcription factor that controls the 
expression of the heterodimeric ABC transporter LmrCD, which is a major 
multidrug transporter in Lactococcus lactis (Lubelski et al, 2006). It is encoded in 
the immediate vicinity of the lmrCD genes and was shown to specifically bind 
to the lmrCD and lmrR promoters where it acts as a transcriptional repressor 
and autoregulator, respectively (Agustiandari et al, 2008). Toxic compounds 
that form substrates of the LmrCD transporter include the DNA-binding drugs 
Hoechst 33342, daunomycin, ethidium bromide and rhodamine 6G. One of 
these drugs, Hoechst 33342, was shown to directly interact with LmrR, and 
its presence in the growth medium induced a significant up-regulation of 
the lmrCD genes (Agustiandari et al, 2008). This strongly suggests that the 
transcription factor may act as a drug-sensor causing stimulation of LmrCD 
production in the presence of toxic compounds, thus promoting their extrusion 
from the cell. By homology LmrR belongs to the PadR family of transcriptional 
regulators found in bacteria and archaea (Gury et al, 2004; Huillet et al, 2006). 
Only a few PadR family members have been functionally characterized, 
showing that these proteins play important roles in the regulation of distinct 
cellular pathways leading, for example, to MDR, virulence and detoxification. 
Crystal structures of two PadR-like proteins, AphA (De Silva et al, 2005) and Pex 
(Arita et al, 2007), revealed the characteristics of the PadR fold, which includes 
a conserved N-terminal winged helix-turn-helix (wHTH) DNA binding domain 




antibiotic resistance repressor MarR (Alekshun et al, 2001), and a highly diverse 
C-terminal helical domain which serves as a dimerization module.
No structural data is available on multi-drug binding transcriptional 
regulators of the PadR family. To understand the structural basis for multi-
drug recognition by LmrR, as well as to provide insights into the molecular 
mechanisms involved in the regulation of lmrCD expression, we have 
determined the crystal structure of LmrR in the apo state, as well as in two drug-
bound states, complexed with Hoechst 33342 and daunomycin, respectively.
ReSULtS 
Structure Determination of LmrR in Apo and Drug-Bound States
Full length LmrR was purified both as a fusion protein containing a C-terminal 
streptactin-tag and as untagged protein. The crystal structure of untagged 
LmrR was determined to 2.0 Å resolution, by the molecular replacement 
method using an ensemble of three structurally homologous, but functionally 
uncharacterized proteins from the Protein Data Bank (PDB) as a search model. 
The untagged LmrR structure was solved in the absence of bound drugs and 
thus represents the apo form. Tagged LmrR was also crystallized in the absence 
of drugs, and its structure was determined at 2.5 Å resolution.  Since the overall 
structural features of drug-free tagged LmrR are identical to those of drug-free 
untagged LmrR, we will describe the latter structure only and refer to it as apo-
LmrR. 
Crystals of drug-bound LmrR were obtained by co-crystallization using tagged 
and untagged LmrR preincubated with different lipophilic cationic drugs. Co-
crystals of tagged LmrR complexed with Hoechst 33342 (H33342) and with 
daunomycin diffracted both to 2.2 Å resolution. Co-crystals obtained with 
untagged LmrR, or in the presence of ethidium bromide and rhodamine 6G, 
could not be used for structure determination because of their poor X-ray 
diffraction quality. In all cases, however, the drug was present as indicated by a 
drug-specific coloring of the crystals.  The structures of LmrR bound to H33342 
and daunomycin were determined by molecular replacement using the apo-
LmrR subunit structure as a search model.
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Each of the three LmrR structures (apo, H33342-bound and daunomycin-
bound) represents a different crystal form with one or two LmrR subunits in 
the asymmetric unit. In all crystals LmrR is present as dimers formed via either 
crystallographic or non-crystallographic symmetry. The dimeric nature of LmrR 
is consistent with the results of gel filtration chromatography and dynamic light 
scattering experiments (not shown), and agrees with the general oligomeric 
preference of other MarR/PadR family members. The overall fold of the LmrR 
dimer is the same in the different structures, but structural superpositions reveal 
some notable differences, highlighting a significant inherent conformational 
plasticity (further explained below). The stereochemical quality of the models 
is excellent with no Ramachandran outliers. The electron density for the 
polypeptide chains is generally well defined, except for the N- and C-termini, 
including the strep-tag, which are disordered and not included in the final 
models. Another flexible region that is disordered in most of the LmrR structures 
comprises the β-wing loop (residues 70-75). The drug-binding site is located at 
the dyad axis of the LmrR dimer. In the LmrR-H33342 complex structure, where 
the dimer is formed by crystallographic symmetry, the Hoechst compound 
binds in two mutually exclusive orientations related by the crystallographic 
dyad symmetry, resulting in an averaged electron density at the drug binding 
site (Supplementary Figure S1A). However, electron density for H33342 is 
well defined, allowing straightforward deconvolution of the two symmetry-
related binding modes. Electron density for the daunomycin molecule in the 
LmrR-daunomycin complex is less well defined (Supplementary Figure S1B), 
indicating some disorder in binding. A summary of the data collection and 
model refinement statistics is presented in Table 1.
Overall Structure of Apo-LmrR
The apo-LmrR crystal contains two independent copies of a subunit in the 
asymmetric unit, which, through a crystallographic dyad rotation axis, form a 
biologically relevant dimer with approximate overall dimensions of 100 Å × 38 
Å × 38 Å (Figure 1). Each LmrR subunit has an (a + β) structure with topology 
a1 (residues 6-23), a2 (residues 28-39), a3 (residues 47-60), β1 (residues 63-67), 
β2 (residues 77-81), a4 (residues 83-108), and is divided into two functional 
domains: a typical wHTH DNA binding domain, which consists of helices a1, 




wing), and a dimerization domain containing the C-terminal helix a4 (Figure 
1A). Helix a4 forms a protruding arm, which in the dimer crosses over to the 
wHTH domain of the dyad-related subunit, packing in a nearly antiparallel 
orientation against helix a1' (the prime indicates the other subunit), as well 
Figure 1. Overall structure of apo-LmrR (A) Ribbon representation of a single LmrR subunit with 
a rainbow color gradient from the N-terminus (blue) to the C-terminus (red). Secondary structure 
elements are indicated with labels. (B) The apo-LmrR dimer is shown in three orientations, 
related by 90º rotations, resulting in a front view  (along the 2-fold rotation axis facing the a4 
helices), a side view (perpendicular to the 2-fold axis) and a back view (along the 2-fold axis 
facing the a1 and a3 helices). Helices are indicated with labels. The left panel shows the LmrR 
dimer in a ribbon presentation, the right panel in electrostatic surface representation. The red 
and blue in the surface representations indicate strength of electrostatic surface potential (red, 
negative charge; blue, positive charge).
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as interacting with the C-terminal region of helix a2' and the loop connecting 
helices a2' and a3' (Figure 1B). Although facing each other at the centre of the 
dimer, there is no interaction between the C-terminal helices a4 and a4', nor 
between N-terminal helices a1 and a1’. Remarkably, this dimeric arrangement 
results in the formation of a large flat-shaped pore (approximately 22 Å in 
width and 6 Å in height) running through the dimer and centered around 
the dyad. The pore entrances are formed by helices a4 and a4' on one side 
(hereafter named the front entrance), and by helices a1, a1', and the two DNA 
recognition helices a3 and a3' on the other side (back entrance). The inside 
of the pore is largely hydrophobic and formed by residues from the N- and 
C-terminal helices of both subunits. The pore centre is constricted by a dyad-
related pair of tryptophan residues (W96 in a4 and a4'), whose indole rings are 
oriented face-to-face at a distance of about 7 Å (as calculated from the centres 
of mass of the indole groups). Clusters of arginine and lysine residues surround 
the back entrance (K6, R10, K55, R59, R75 and K77 from each subunit) resulting 
in a net positive surface charge, which is consistent with that side of the dimer 
forming the binding site for DNA. By contrast, the surface around the front 
entrance is largely negatively charged due to the presence of twelve Glu and 
Asp residues, six from each C-terminal helix in the dimer (E83, E87, E94, D100, 
E104 and E107). The opposite electrostatic surface charges around the front 
and back entrances (Figure 1B) create a small but significant overall molecular 
dipole moment (1192 Debye) running through the pore coinciding with the 
dyad axis. 
the dimer interface
A striking feature of the LmrR structure is its unusual dimeric arrangement 
leading to the formation of a large central pore.  As pointed out above the 
dimer interface is formed by interactions of the C-terminal helix of each 
subunit with the DNA-binding domain of its dimer mate. The surface area 
of one subunit that becomes buried upon dimerization is ~1160 Å2, which is 
within the expected range for a stable dimer considering the 13.5 kDa size 
of the LmrR subunit (Janin et al, 1988). However, the buried surface area in 
the LmrR dimer is substantially smaller than the buried surface areas in other 
MarR/PadR dimers (e.g. the buried surface area in the MarR dimer is 3700 Å2), 




formation of a central compact core. Stabilization of the LmrR dimer mainly 
occurs via hydrophobic interactions. Residues in helix a4 that participate in 
forming the dimer interface are L91, A92, W96, R98, V99, I102, I103, N105 and 
L106. In the wHTH domain of the dimer-related subunit the residues important 
for dimerization are M8', A11', Q12', V15', I16' and V20' (from helix a1'), and V35', 
A38', N40', and M43' (from helix a2' and the loop connecting helices a2' and 
a3'). A few interactions are of polar or ionic nature. For example the side chain 
of N105 forms a hydrogen bond with the main chain oxygen of A38', and a salt 
bridge is formed between R98 and E42'. Another notable residue at the dimer 
interface is Q12' in helix a1'. The side chain of this residue forms a hydrogen 
bond with S95 in helix a4, and makes a p-cation interaction with W96 at the 
back face of the indole rings (assigning the one exposed towards the pore as 
their front face), thus stabilizing the conformation of this central residue in the 
pore.  
Comparison with other winged helix proteins
A search of the PDB using the Dali server (Holm & Sander, 1996) showed that 
the LmrR subunit has significant structural homology to various DNA binding 
proteins containing helix-turn-helix or winged helix-turn-helix domains. 
Among these are the structurally and functionally characterized MarR/PadR 
family members MarR of E. coli (PDB accession code 1JGS, 87 equivalent Ca-
atoms were superimposed with a root-mean-square-deviation (RMSD) of 2.3 
Å), OhrR of B. subtilis (1Z9C, 86 equivalent Ca-atoms were superimposed with 
a RMSD of 2.8 Å), AphA of Vibrio cholerae (1YG2, 82 equivalent Ca-atoms were 
superimposed with a RMSD of 3.7 Å) and Pex of Synechococcus sp. (2E1N, 78 
equivalent Ca-atoms were superimposed with a RMSD of 1.8 Å). The structural 
similarities of LmrR with the MarR/PadR proteins are mainly confined to its 
wHTH domain and the sequence identities are rather low (ranging from 11% 
for MarR to 28% for Pex). Interestingly, structural similarity was also detected 
with a number of hypothetical transcriptional regulators in the PDB, for which 
structures and function have not been published. One such protein, from 
Clostridium thermocellum, showed a particularly high structural homology with 
LmrR (PDB accession code 1XMA, 99 equivalent Ca-atoms were superimposed 
with a RMSD of 2.7 Å and a sequence identity of 35%). A structure-based 
sequence alignment of LmrR with 1XMA, AphA, MarR and OhrR is presented 
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in Figure 2A. Most of the conserved residues are hydrophobic and appear to 
be important in stabilization of the overall fold of the DNA binding domain. 
Currently, the only MarR/PadR protein for which a DNA-bound structure is 
known is OhrR (Hong et al, 2005). The regions in LmrR that are equivalent to 
the DNA binding site in OhrR, i.e. helix a3 and the β-wing, show the highest 
Figure 2. Comparison of LmrR with other wHTH proteins. (A) Structure-based multiple sequence 
alignment computed with the Tcoffee web server (Poirot et al, 2003) and visualized with JalView 
(Clamp et al, 2004). Structures were taken from the PDB using the following accession numbers: 
1XMA, 1YG2 (AphA), 1JGS (MarR) and 1Z9C (OhrR). Residues of LmrR involved in dimerization 
are indicated with green dots, residues involved in drug binding with grey dots, and residues 
in OhrR involved in DNA binding are indicated with blue dots. (B) Ribbon representations of 
the LmrR and 1XMA dimers. Equivalent secondary structure elements are indicated in specific 




degree of conservation. Nevertheless, among the conserved residues only a 
few have a role in specific DNA binding in OhrR, suggesting that LmrR and OhrR 
recognize different DNA sequences. Interestingly, the putative DNA-binding 
sites of LmrR and 1XMA are highly conserved, which may indicate that these 
proteins bind similar DNA sequences. Unfortunately, the specific DNA binding 
sequence(s) of LmrR within the lmrR and lmrCD promoters have not yet been 
delineated (Agustiandari et al, 2008), and for the C. thermocellum homolog the 
target promoters are unknown. The comparison of LmrR with the four MarR/
PadR transcription factors further reveals two invariant residues, G61 and G85, 
which are found in regions that connect the β-wing to helices a3 and a4 and 
appear to have crucial structural roles in stabilizing the conformation of the 
β-wing relative to the DNA recognition helix and the dimerization domain. 
Another invariant residue is T82, which is located at the proximal end of the 
wing between β2 and helix a4. Previously, it was shown that a T82I mutation 
in LmrR is associated with drug-resistant phenotypes of L. lactis (Lubelski et al, 
2006), and that the LmrR-T82I mutant is deficient in both drug and DNA binding 
(Agustiandari et al, 2008). In the LmrR structure the side chain hydroxyl group 
of T82 is making three hydrogen bonds, with the backbone carbonyl of G61 
at the N-terminal end of the β-wing and with the backbone amides of I84 and 
G85 at the N-terminus of helix a4, while the main chain amide of T82 forms a 
hydrogen bond with the backbone carbonyl of I62 (Supplementary Figure S2). 
These interactions are conserved in the other MarR/PadR structures, and appear 
to clamp the β-wing in place and stabilize the C-terminal helix. Replacement of 
T82 by an isoleucine residue will result in the loss of at least three of the four 
hydrogen bonds, as well as in the introduction of significant steric strain due to 
the presence of a bulkier and more hydrophobic side chain. The T82I mutation 
thus is predicted to induce a structural perturbation of LmrR, which probably 
corresponds to a detachment of the β-wing and a disordering of its C-terminal 
helix. Such a structural perturbation would explain the deleterious effect of 
the T82I mutation on overall LmrR function.
The structural organization of the LmrR dimer, with the two DNA-binding 
domains adjacent to one another and their DNA recognition helices facing the 
same side, is like in other MarR/PadR family members, pointing to a similar 
mode of DNA binding with the recognition helices fitting into two successive 
major grooves on one side of the DNA double helix. However, the dimeric 
architecture of LmrR is unique: none of the other structurally characterized 
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MarR/PadR family members shows a central pore at the dimer interface. 
It should be noted, though, that the dimerization modules in MarR/PadR 
proteins are highly diverse, consisting of different numbers of a-helices packed 
together in various ways. Of the four proteins that were compared with LmrR, 
only 1XMA has an identical overall topology containing a single C-terminal 
dimerization helix. Interestingly, the sequence homology of LmrR with 1XMA 
extends into the C-terminal helix and among the conserved residues are 
W96, as well as residues near the C-terminus that in LmrR participate in dimer 
formation. Nevertheless, unlike in LmrR, in the C. thermocellum transcription 
factor the N- and C-terminal helices of the two subunits form a compact core 
at the dimeric interface that is completely closed. This difference at the dimer 
interface is coupled to a difference in the relative orientation of the C-terminal 
helices with respect to the wHTH domains and to significant bending of the 
N- and C-terminal helices (Figure 2B), which allow the subunits in the dimer 
of the C. thermocellum transcription factor to approach each other more 
closely than the subunits in the LmrR dimer. To predict whether the “closed” 
conformation of the 1XMA dimer would be accessible to LmrR, a 1XMA-based 
homology model was prepared of LmrR using the SWISS model server (http://
swissmodel.expasy.org/). The results indicate that there are no major steric 
clashes that would prevent LmrR to adopt a “closed” conformation. However, 
in comparison with the 1XMA dimer, the conserved tryptophan pair and 
their surrounding residues in LmrR seem unsuitable to provide the necessary 
hydrophobic packing and interactions to stabilize a closure of the central pore 
(Supplementary Figure S3). On the other hand, additional overall conformation 
changes and rearrangements of side chains could perhaps create a well-
packed hydrophobic core. Clearly, homology modeling alone is not sufficient 
to assess the likelihood of LmrR also adopting a “closed” conformation. More 
sophisticated methods, like molecular dynamic simulations or NMR, could 
perhaps provide an answer, but these are beyond the scope of the present 
study. 
Binding of hoechst 33342 and Daunomycin
The structures of LmrR bound with H33342 and daunomycin reveal that the 
central pore in the LmrR dimer serves as a multi-drug binding site (Figure 3). 




with the 1:2 (drug:LmrR subunit) stoichiometry of drug-binding obtained 
previously from fluorescent titrations with H33342 (Agustiandari et al, 2008). 
The two drugs show a common mode of binding: their flat ring systems are 
wedged in between the W96 and W96’ side chains forming aromatic stacking 
interactions with each of the two indole systems (Figures 3C-D). Further 
stabilization of the bound drugs is provided by various hydrophobic contacts 
in the pore. Remarkably, no hydrogen bonds are observed between the 
Figure 3. Crystallographic analysis of drug binding to LmrR. (A) Chemical structures of H33342 
(left) and daunomycin (right). (B) Ribbon diagrams of the LmrR-H33342 (left) and LmrR-
daunomycin (right) complex, showing the drug molecule (sticks) bound inside the central pore 
of the dimer in between the two tryptophan residues W96 and W96' (sticks). The two subunits 
of the LmrR dimer, as well as W96 and W96' are colored with different shades of green. (C) Close-
up stereo view of the drug-binding pore in the LmrR-H33342 complex depicting the drug and 
residues that contact the drug (maximum contact distance defined as 4 Å). (D) Similar stereo 
view as in C of the drug-binding pore in the LmrR-daunomycin complex.
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protein and the drugs.  Rather, the orientation of the drugs is such that most 
of their polar atoms are in a solvent exposed position facing the front or back 
entrances of the pore. Several bound water molecules are present in the pore 
to act as hydrogen bond partners of the drugs.
The two drug-bound LmrR structures also show substantial differences. 
The elongated crescent-shaped Hoechst compound deeply penetrates the 
Figure 4. Spectroscopic and mutational analysis of drug and DNA binding by LmrR. (A) 
Fluorescence titration curves measuring H33342 and daunomycin binding to LmrR. Binding of 
H33342 was monitored by recording the increase in drug fluorescence when titrating a solution 
of wild-type LmrR with increasing concentrations of H33342, using experimental conditions 
as described (Agustiandari, 2008). Binding of daunomycin was monitored by performing 
tryptophan fluorescence quenching titration of the LmrR mutant W67Y with increasing 
concentrations of daunomycin. The apparent KD values are calculated from the fitting of the 
data using non-linear regression analysis (r2=0.993 and 0.996 for H33342 and daunomycin, 
respectively). Inset, tryptophan-fluorescence-emission spectra in the presence of increasing 
concentrations of daunomycin. (B) Fluorescence titration curves measuring H33342 binding to 
the W67 and W97 single mutants and the W67Y/W96Y double mutant of LmrR. The binding 
curves for the W96 single mutants, as well as the W67A/W96Y double mutant, are flat, thus 
revealing that these mutants lack drug-binding capability. (C) Electrophoretic mobility shift 




pore and stretches out over its entire width with the ethoxy-phenolic and 
N-methyl-piperazine groups extending towards the sidewalls and facing the 
back entrance of the pore. The area of the drug-protein interaction surface is 
substantial (~215 Å2) and shows good shape-complementarity. W96 and W96’ 
clamp down one of the central benzimidazole ring systems, which is aligned 
in an off-centered parallel orientation with respect to each of the two indole 
rings. The inter-ring distances are ~3.5 Å, optimal for allowing the formation of 
strong van der Waals interactions (McGaughey et al, 1998)
Less extensive interactions are formed with daunomycin. The presence 
of the bulky amino sugar substituent prohibits a deep penetration of the drug 
into the flat pore (Figure 5C). Only the aglycon chromophore interacts with the 
protein, while the amino sugar is exposed to the solvent at the front entrance 
of the pore. As a consequence the area of the drug-protein interaction surface 
in the LmrR-daunomycin complex is much smaller (~82 Å2) than in the 
LmrR-H33342 complex. No electron density could be observed for the amino 
sugar of daunomycin, indicating that this substituent is highly flexible. The 
stacking interactions of the aromatic rings with the W96/W96’ pair form the 
main contribution to drug binding stabilization, but the stacking geometry 
is less optimal than in the LmrR-H33342 complex. The weaker interactions 
between LmrR and daunomycin, as compared to the interactions between 
LmrR and H33342, are further illustrated by the relatively high atomic B-factors 
of daunomycin (Table 1).
Drug Binding Affinities and Importance of W96 for Drug and DNA 
Binding
To quantify the difference in binding affinity of LmrR for H33342 and daunomycin 
the dissociation constants of the two drugs were approximated from binding 
curves obtained from two different, fluorescence-based drug-binding assays 
(Figure 4A). Binding of H33342 to untagged LmrR was monitored by recording 
the increase in drug fluorescence when H33342 moves from an aqueous to 
a hydrophobic environment, i.e. when it binds to the drug binding site of 
LmrR. The apparent dissociation constant of H33342 obtained from fitting the 
binding curve was ~20 nM, showing that this compound has a strong affinity 
for the drug binding site of LmrR. Unfortunately, the spectral properties 
of daunomycin did not allow the use of a similar binding assay. Instead, for 
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daunomycin, we obtained a binding curve by measuring the fluorescence 
quenching of W96 upon titration of the drug. LmrR contains two tryptophan 
residues, W67 and W96, the former of which is located in the β-wing of the 
DNA binding domain. To avoid unwanted disturbances of the fluorescence 
signal, W67 was mutated to either alanine or tyrosine. The W67Y and W67A 
mutations had no significant effect on the binding of H33342 by LmrR, nor 
on the binding of lmrCD promoter DNA (Figures 4B and 4C). The dissociation 
constant of daunomycin, determined from W96-fluorescence quenching using 
the LmrR-W67Y mutant, was ~0.25 mM, confirming that its binding affinity for 
LmrR is weaker than that of the Hoechst compound. 
To confirm its importance for drug binding, W96 was also mutated to 
alanine or tyrosine. Both these LmrR mutants, W96A and W96Y, lost the ability 
to bind H33342 (Figure 4B). Interestingly, although the W96Y mutant was 
still able to bind to the lmrCD promotor, the W96A mutant was not, nor was 
a W67Y/W96Y double mutant (Figure 4C). The impaired DNA binding of the 
W67Y/W96Y mutant is not due to a loss of structural integrity of the protein, as 
was assessed by circular dichroism (Supplementary Figure S4A). These results 
thus point to some indirect role in DNA binding for residue 96, in addition to a 
direct role in drug binding. 
Conformational flexibility
As pointed out earlier notable conformational differences were identified 
between the different LmrR structures (Figure 5). Pair-wise structural 
superpositions of the isolated subunits in the different dimers, using all Ca 
atoms, result in root-mean-square deviations ranging from 1.0 to 2.0 Å.  These 
deviations primarily result from differences in the orientation of the C-terminal 
helix a4 relative to the wHTH domain. The reorientations of helix a4 may be 
described as lever-arm rotations with the residues that attach the N-terminus 
of the helix to the wHTH domain serving as a hinge (Figure 5A). 
Even though the rotations are small (varying between 9° and 16°), the 
lever-like movement results in substantial translational shifts of residues near 
the C-terminus of helix a4 (up to ~8 Å as calculated from Ca-Ca distances). 
Except for small shifts of helices a1 and a2 no significant conformational 
changes are observed in the wHTH domains. Via the dimeric interface the 




differences in the LmrR dimeric structures. Firstly, when comparing the 
H33342-bound and daunomycin-bound LmrR dimers with the apo-LmrR 
dimer, one of the wHTH domains is rotated relative to the wHTH domain of the 
other subunit. The amounts of rotation are about equal for both drug-bound 
complexes (~14°), but the rotations are in opposite directions (Figure 5B). 
In fact, the largest conformational change (~28° rotation) is observed when 
mutually comparing the H33342-bound and daunomycin-bound LmrR dimers. 
The rotations of the wHTH domains are coupled to changes in the spacing 
between the two DNA recognition helices. The shortest spacing is observed 
Figure 5. Conformational differences between the apo and two drug-bound structures of LmrR. 
(A) Superposition (in ribbon representation) of the apo-LmrR subunit structure (yellow) and 
the subunit structures of H33342-bound (green) and daunomycin-bound LmrR (salmon). The 
superposition was carried out using the Ca-atoms of the wHTH domain. (B) Superposition of the 
three LmrR dimers, showing the difference in relative position of the two wHTH domains. Only one 
of the two subunits (light colors) was used for the superposition (identical to the superposition 
in Figure 5A). Indicated are the range of distances between the two DNA recognition helices in 
the different dimers, and the largest rotational shift of the wHTH domains (based on comparing 
the H33342-bound and daunomycin-bound dimers). (C) The same superposition as in Figure 5B, 
but from a different view, showing the relative shifts of helix pair a1-a4’ with respect to helix pair 
a1’-a4. Also shown in sticks are H33342 (green) and daunomycin (salmon), as well as the W96/
W96’ tryptophan pair. The sugar moiety of daunomycin is shown in a solvent exposed position 
at the front entrance of the pore, but it should be noted that its binding is highly disordered, as 
evident from the weak electron density associated with this substituent.
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in the daunomycin bound complex with a distance of ~26 Å (measured from 
the centroids of the helices), while in the H33342 bound complex the spacing 
is the largest with a distance of ~32 Å. Secondly, inside the pore differences are 
observed in the orientations of residues from one subunit relative to those of 
the other subunit. These differences are caused by shifts of the a1-a4’ helix pair 
relatively to the a1’-a4 helix pair in the different LmrR structures, and directly 
affect the geometry of the central drug-binding site (Figure 5C). 
Unfortunately, since each crystal structure of LmrR represents a different 
crystal form, it is not possible to distinguish whether the conformational 
changes are drug-induced, or whether they are caused by differences in crystal 
packing. However, the observed structural differences point to a remarkable 
plasticity of LmrR. As the conformational rearrangements affect both the drug 
binding and DNA binding sites in the LmrR dimer, similar conformational 
changes likely play an important role in the induction mechanism of LmrR.
DISCUSSION
The crystal structure of LmrR is the first structure of a transcription factor 
regulating the expression of a multi-drug ABC transporter. It is also the first 
time that the structural basis of multi-drug recognition has been studied for a 
PadR transcriptional regulator. Current knowledge of the mechanism of multi-
drug recognition by transcriptional regulators of multi-drug transporters is 
largely based on crystallographic studies with the transcription factors BmrR 
from Bacillus subtilis (Zheleznova et al, 1999), QacR from Staphyloccoccus 
aureus (Schumacher & Brennan, 2003; Schumacher et al, 2001) and TtgR from 
Pseudomonas putida (Alguel et al, 2007). The structures of LmrR bound to H33342 
and daunomycin confirm the importance of several of the general structural 
features that seem important in multi-drug recognition, e.g. the availability of 
a large drug-binding pocket that can accommodate a large spectrum of drug 
ligands, the importance of aromatic and hydrophobic residues for providing 
van der Waals interactions to stabilize the bound ligands, the importance of 
water molecules for occupying regions of the pocket not occupied by the 
ligand and for solvating hydrophilic groups of the ligand that do not interact 
with the protein, and a flexible pocket wall that can change conformation 
upon ligand binding. However, there are also some striking differences in the 




QacR. The foremost difference is that in LmrR the multi-drug binding pocket 
is formed by a symmetric pore located at the dimer centre with both subunits 
contributing equally to its architecture. In QacR and BmrR the drug-binding 
pockets are asymmetric and primarily formed within a single subunit. Also, 
in the drug-bound LmrR complexes the binding modes of the two different 
drugs are very similar and involve a common and strong aromatic stacking 
interaction with the W96/W96’ tryptophan pair. In the other transcription 
factors the architecture of the drug-binding pockets allows different ligands 
to adopt different orientations within the pocket and to interact with different 
sets of amino acids. In BmrR and QacR, the binding affinity for cationic drugs 
is further augmented by electrostatic attraction between the positively 
charged ligand and buried or partially buried negatively charged glutamates 
or aspartate residues of the protein. No such interactions were observed in the 
H33342- and daunomycin-bound LmrR structures. However, in LmrR positive 
charges in the drugs may be stabilized by long-range electrostatic interactions 
with the cluster of glutamate and aspartate residues that surround the front 
entrance of the pore. Also the apparent molecular dipole moment that was 
found running through the pore of LmrR may assist in attracting and binding 
cationic drugs. The relevance of this latter feature of the LmrR structure for 
drug specificity is however unclear: it could be likewise important for directing 
LmrR towards the DNA substrate. 
It is evident that the homology of LmrR with other members of the 
PadR protein family that have so far been functionally and structurally 
characterized, i.e. AphA and Pex, is relatively low. Our results thus confirm 
the classification of two PadR-subfamilies (Huillet et al, 2006): subfamily I 
with longer sequences (~180 amino acids) to which AphA and Pex belong, 
and a more distant subfamily II with shorter sequences (~110 amino acids) 
to which LmrR belongs. To the best of our knowledge LmrR is so far the only 
member of the PadR subfamily II that has been characterized both functionally 
and structurally. Interestingly, a BLAST search against translated nucleotide 
sequence databases (see Supplementary Figure S5) yields a large number of 
close homologs of LmrR that exist in various bacterial species, in particular those 
belonging to the Firmicutes (Listeria, Bacillus, Staphylococcus, Enterococcus, 
Lactobacillus, Streptococcus, Clostridium). Both the N- and C-terminal domain 
of LmrR are significantly conserved in these proteins, including W96, thus 
pointing to a high similarity in overall structure and dimeric organization. 
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Likely, some of these proteins also have a similar role as LmrR in regulating 
multi-drug resistance, but lack of functional data prohibits such assessment for 
the moment. Furthermore, the sequence conservation in the C-terminal helix 
of these LmrR-like proteins is no guarantee for the existence of a central multi-
drug binding pore, as is evident from the structural comparison of LmrR with 
the C. thermocellum homolog. Future studies should therefore reveal whether 
the multi-drug binding characteristics of LmrR are applicable to a larger set of 
proteins.   
In the absence of a DNA-bound structure, the induction mechanism of 
LmrR remains to be determined. Comparison of the different LmrR structures, 
and the effects of the W96 mutations, reveals a possible allosteric coupling 
between the drug and DNA binding sites. Most likely the binding of a drug 
to LmrR locks the dimer in a conformational state that is incompatible with 
DNA binding, due to a relative positioning of the DNA recognition helices 
that is unsuitable for their simultaneous insertion in the successive major 
grooves of the DNA. Such an induction mechanism would be similar to the 
induction mechanism of various wHTH-domain containing transcription 
factors, although the origin and nature of the structural changes involved 
in this mechanism are likely to be different for LmrR. To explore this further 
we tested the suitability of the different LmrR structures to bind B-form DNA 
using model building. None of the three LmrR structures has a conformation 
that allows a good fit with DNA (Supplementary Figure S6). In daunomycin-
bound LmrR the DNA recognition helices are spaced too close together and 
would sterically clash with the DNA. In contrast, in the apo form and H33342-
bound complex of LmrR they are positioned too far apart, and one of the two 
wHTH DNA binding domains is shifted away from the DNA. It should be noted, 
though, that such modeling does not take into account the possibility of DNA 
distortion, thus limiting its significance. Further studies are underway to better 
define the DNA binding characteristics of LmrR and unequivocally identify its 
operator DNA sequence. This knowledge will be crucial to allow crystallization 






H33342 (Molecular Probes) and daunomycin (Calbiochem) were purchased 
and used without further purifications. 
Protein production, crystallization and X-ray data collection
Tagged LmrR, comprising full length LmrR (from L. lactis strain MG1363) 
and a C-terminal streptactin-tag (117-SRWSHPQFEK-126), was obtained 
by nisin-induced overexpression in L. lactis using the expression vector 
pNSC8048-lmrR, and initially purified via strep-tag affinity and heparin column 
chromatography as described elsewhere (Agustiandari et al, 2008). Final 
purification to homogeneity was achieved by size exclusion chromatography 
on a Superdex 200 10/300 GL column (GE Healthcare) with a running buffer 
containing 20 mM Tris-HCl, pH 8.0, 280 mM NaCl and 1 mM EDTA. To anticipate 
possible negative effects of the streptactin-tag on protein crystal growth or 
protein conformation, also untagged full length LmrR was produced using 
a modified version of the overexpression plasmid in which the strep-tag 
encoding sequence was deleted. Untagged LmrR was first purified on a heparin 
column with conditions similar to those used for tagged LmrR, followed by 
purification on a Mono S HR 5/5 cation exchange column (GE Healthcare) with 
a linear gradient of 0.03-1 M NaCl (20 mM Hepes, pH 8, 1 mM EDTA, 0.5 mM 
DTT). Finally, the protein was loaded on a Superdex 200 10/300 GL column and 
eluted using the same running buffer as for tagged LmrR. 
Purified LmrR, with or without streptactin-tag, was concentrated in the 
gel filtration running buffer and either used immediately for crystallization or 
frozen in liquid nitrogen and stored at -80 ºC. Crystallization trials were set up 
with the aid of an Oryx6 crystallization robot (Douglas Instruments) using the 
PACT and JCSG crystallization screens (Newman et al, 2005). Lead conditions 
were optimized manually using the sitting drop vapor diffusion method with 
crystallization drops containing 1 μl of the protein solution (8 mg/ml) and 
1 μl of the reservoir solution. Crystals of drug-bound LmrR complexes were 
obtained by co-crystallization using a LmrR solution (8 mg/ml) preincubated 
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for 30 minutes with 2 mM H33342 or daunomycin. Diffracting crystals of 
LmrR in drug-free conditions were obtained with both tagged and untagged 
protein, while in the drug-bound form only streptactin-tagged LmrR yielded 
well diffracting crystals. At drug-free conditions tagged LmrR crystals were 
obtained with 20% PEG 3350 in 0.1 M Bis-Tris propane, pH 8.5 and 0.2 M 
NaNO3, while drug-free untagged LmrR crystals grew in 30% PEG 1500, 0.1 
M propionic acid/cacodylate/Bis-Tris propane (PCB) cocktail buffer, pH 8.5. 
Crystals of H33342-bound LmrR grew against a well solution containing 25% 
PEG 1500, 0.1 M succinic acid/phosphate/glycine (SPG) buffer, pH 9.0, while 
crystals of daunomycin-bound LmrR-strep were obtained with 25% PEG 
1500, 0.1 M malonic acid/imidazol/boric (MIB) buffer, pH 7.0. All crystals grew 
overnight at room temperature. 
X-ray diffraction data were collected at cryogenic temperatures by using 
the MX beam lines of the European Synchrotron Radiation Facility (ESRF) at 
Grenoble. Prior to data collection, crystals were flash cooled in a cryoprotectant 
solution of mother liquor with 20% glycerol. The data were processed with 
MOSFLM (Leslie, 2006) and merged using SCALA as implemented in CCP4 
(Winn et al, 2011). Relevant data statistics are shown in Table 1.  Data on the 
tagged LmrR crystal grown in the absence of drugs, and its derived structure, 
will not be presented here, as they were merely used to verify that the 
C-terminal streptactin-tag did not affect the overall LmrR structure.
Structure determination of apo-LmrR
In the absence of drugs untagged LmrR crystallized in space group C2221 with 
two subunits from two different dimers in the asymmetric unit. The crystals 
diffracted up to 2.0 Å resolution. The untagged apo-LmrR structure was solved 
by molecular replacement using PHASER with the automated search process 
(McCoy, 2007). Various search models were prepared and tried using the 
structures of homologous proteins from the PDB, as identified by the FFAS 
server (Jaroszewski et al, 2005). Molecular replacement succeeded with a 
search ensemble containing the structures of three hypothetical transcription 
factors (PDB entries 2ESH, 1YYV and 1XMA) having sequence identities with 
LmrR ranging from 15% to 34%. Phase improvement and construction of an 
initial protein model was performed by using the automatic map improvement 






















Resolution (Å) 35 - 2.0 65 - 2.2 70 - 2.2
Rmerge 
a 0.04 (0.5)b 0.05 (0.206) 0.036 (0.273)
Mean I/�I 46.6 (2.0) 21.1 (4.8) 28.9 (3.8)
Completeness (%) 100 (99.3) 99.8 (99.0) 96.0 (99.9)
Unique reflections 15006 6948 17020
Redundancy 6.7 (7.8) 3.9 (2.9) 3.0 (3.5)
Refinement statistics
Resolution (Å) 23 - 2.0 50 -  2.2 50 - 2.2
Rwork/Rfree
c 0.21/0.26 0.20 / 0.25 0.23/0.27
No. of non-H atoms
Protein 1679 850 1859
Ligand - 34 38
Waters 83 27 116
Root-mean-square 
deviations in
bond length (Å) 0.011 0.015 0.019
bond angles (º) 1.4 1.0 0.8
Average B-values (Å2)
Protein 15 36 27
Ligand - 42 74
Ramachandran analysis
Most favoured (%) 99.0 98.0 98.0
Additional allowed (%) 1.0 2.0 2.0
a R
merge
 = ��|Ihkl − Ihkl(j)|/ �Ihkl, where Ihkl(j) is the observed intensity and Ihkl is the final average 
intensity value. 
b Values in parentheses are for the highest-resolution shell. 
c Rwork = �||Fobs| − |Fcalc||/�|Fobs| and Rfree = �||Fobs| − |Fcalc||/�|Fobs|, where all reflections belong to a test 
set of 10% randomly selected data.
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was obtained by carrying out various cycles of refinement using REFMAC 
(Murshudov et al, 1997) interspersed with cycles of rebuilding and placement 
of water molecules using COOT (Emsley & Cowtan, 2004). TLS refinement 
was used in the last refinement cycles to model anisotropic displacements 
(Winn et al, 2001; Winn et al, 2003). The final model of the apo-LmrR structure 
contains two polypeptide chains: one discontinuous chain covering residues 
5-70 and 75-109, and one continuous chain covering residues 5-109. In both 
polypeptides residues 1-4 and 110-116 are missing due to weak or absent 
electron density. Each polypeptide is one subunit of different biological dimers 
that are formed by crystallographic 2-fold axes. 
Structure determination of drug-bound LmrR
H33342-bound LmrR crystals belong to space group P43212 with one 
monomeric molecule per asymmetric unit, while daunomycin-bound LmrR 
crystallized in a different space group (P212121) with a dimer in the asymmetric 
unit. The structures of the drug-bound complexes were solved by molecular 
replacement using the apo-LmrR monomer as a search model. Clear density 
in 2Fo-Fc and Fo-Fc Fourier maps, calculated at the initial stages of refinement, 
indicated the location and binding mode of the drugs. The model building and 
refinement were done with COOT and REFMAC5. In both cases TLS refinement 
was used in the last refinement cycles.  For the LmrR-H33342 complex the final 
protein model contains residues 3-108. No electron density is observed for 
residues 1-2, 109-126 (including the strep-tag) and 71-73 (β-wing) loop. The 
final protein model of LmrR-daunomycin contains residues 2-116 for chain A, 
and residues 5-115 for chain B. 
Structure analysis
Relevant crystallographic statistics of the refined models are shown in Table 
1. Stereochemistry of the models was validated with the programs Procheck 
(Laskowski et al, 1993) and MolProbity (Davis et al, 2007). 3D structural 
superpositions and assessment of conformational differences was carried 
out with the programs Lsqman (Kleywegt, 1999) and Dyndom (Hayward & 




(Baker et al, 2001) and visualized using PyMOL (Delano Scientific). The molecular 
dipole moment of the LmrR dimer was calculated using the protein dipole 
moments server at http://bioportal.weizmann.ac.il/dipol. Additional analyses, like 
calculation of surface areas, were performed with various programs from the 
CCP4 program suite (Win et al, 2011). 
Site directed mutagenesis
Mutations of W67 and W96 in the lmrR gene were performed via round PCR 
using the pNSC8048-lmrR plasmid as the template together with synthetic 
primers containing the designated mutations. PCR products were ligated at 
4˚C overnight before being transformed to L. lactis NZ9000 competent cells 
via electroporation. Selected colonies were inoculated at 30˚C in M17 media 
(Difco) supplemented with 0.5% glucose (w/v) and 5 µg/ml chloroamphenicol. 
Plasmid isolation was performed using GenElute Plasmid miniprep kit (Sigma-
Aldrich) and the correct mutations were verified by nucleotide sequencing. 
Drug binding assays
Binding of H33342 to the DNA-free purified LmrR variants was monitored by 
the increase of H33342 fluorescence upon binding as described previously 
(Agustiandari et al, 2008). Binding of daunomycin to LmrR mutant W67Y was 
monitored by tryptophan fluorescence quenching titration experiments using 
an Aminco Bowman Series 2 spectrofluorometer (excitation wavelength of 295 
nm, emission spectra obtained from 300 to 450 nm). A detailed description of 
the drug binding assays, additional control experiments, and the procedure 
that was followed to derive the apparent dissociation constants (Kd) of the two 
drugs is included in the Supplementary Information. 
DNA binding assay
The ability of the LmrR variants to bind to a 287 bp fragment corresponding 
to the promoter region of lmrCD was studied by means of an electrophoretic 
mobility shift assay (EMSA) as described (Agustiandari et al, 2008).




Circular dichroism spectra were obtained at 25 ºC by using an Aviv 62ADS 
spectropolarimeter (Aviv Associates, Lakewood, NJ). The protein samples 
contained 0.24 mg/ml protein in 20 mM Tris-HCl, pH 8.0, and 50 mM NaCl. 
Accession Numbers 
The atomic coordinates and structure factors for apo-LmrR (entry 3F8B), 
H33342-bound LmrR (entry 3F8C), and daunomycin-bound LmrR (entry 3F8F) 
have been deposited in the Protein Data Bank, Research Collaboratory for 
Structural Bioinformatics, Rutgers University (http://www.rcsb.org).
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Supplementary materials and methods
Drug binding assays — Protein concentrations were calculated from the 
absorbance at 280 nm (A280). The H33342-binding assay was performed as 
follows: to a solution of purified LmrR (0.2 µM as dimer) in 50 mM Tris-HCl, pH 7.0, 
increasing amounts of H33342 were added and the fluorescence was followed 
at excitation and emission wavelengths of 355 and 457 nm, respectively, 
with slit widths of 5 nm using a Perkin-Elmer LS 50B spectrofluorometer at 
room temperature. Fluorescence data were corrected as described previously 
(Agustiandari et al, 2008). To monitor the binding of daunomycin to LmrR 
the following procedure was employed. To a solution of LmrR (0.15 μM of 
dimeric species, 120 μl) in 50 mM Tris-HCl, pH 8.0, small volumes (1.2 μl) of a 
daunomycin stock solution were added in sequential steps. After each titration 
step the solution was mixed thoroughly and incubated for 2 minutes before 
measurements were made. Tryptophan fluorescence was recorded at room 
temperature with an Aminco Bowman Series 2 spectrofluorometer using a 
0.2 ml cell and an excitation wavelength of 295 nm. Emission spectra were 
obtained from 300 to 450 nm. The excitation and emission slit widths were 4 
nm. Each spectrum was scanned twice to obtain the final fluorescence emission 
spectra. Spectra were corrected for background emission and dilution effects.
Apparent dissociation constants (Kd) of the two drugs were obtained by data 
fitting using non-linear regression analysis (program LabFit), employing the 
following equation (Zsila et al, 2004):
where RF is either the relative increase in fluorescence intensity (DF) of 
H33342 upon binding to LmrR (expressed as (I-I0)/(Imax-I0), with I0 the intensity 
of fluorescence in the absence of ligand, I the intensity of fluorescence upon 
addition of ligand and Imax the maximum intensity of fluorescence at saturation) 
or the tryptophan fluorescence quenching (DQF) by daunomycin at 340 nm 
(expressed as (I0-I)/I0, with I0 the intensity of fluorescence in the absence of 
quencher and I the intensity of fluorescence upon addition of quencher). Cp 
and CL are the total concentrations of protein and ligand (drug), respectively, 




Control experiments — As a control the drugs were titrated to a solution of 
the neutral tryptophan analog N-acetyl-tryptophanamide (0.4 mM) in 20 mM 
Tris-HCl, pH 8.0, 270 mM NaCl, and the fluorescence data were recorded using 
an identical setup as with the LmrR protein solution. No significant changes 
in fluorescence were recorded (Supplementary Figures S4B-C), thus showing 
that the changes in fluorescence recorded for drug titration in the presence of 
LmrR are protein-driven, and not merely the result of an intrinsic affinity of the 
drugs for tryptophan. 
Figure S1 The binding of H33342 and daunomycin to LmrR. (A) σA-weighted Fo-Fc omit 
electron-density for bound H33342 (in sticks, showing the two binding modes that are related 
by the crystallographic dyad). Carbon atoms are shown in yellow or cyan (to distinguish the 
two binding modes), oxygen in red and nitrogen in blue. (B) σA-weighted Fo-Fc omit electron 
density for bound daunomycin. To remove model bias, the protein models (after removing the 
drugs) were subjected to 30 rounds of refinement by REFMAC (Murshudov et al, 1997), prior to 
map calculation. The contour level of the maps is 3σ (H33342) and 2.5σ (daunomycin) and the 
resolution is 2.2 Å. 
Figure S2 Stereo view showing the environment and interactions of T82 in the apo LmrR 
structure. Hydrogen bonds are indicated with dashed lines. 
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Figure S3 Assessment of LmrR adopting a 1XMA-like “closed” conformation. (A) Stereo view of 
the centre of the 1XMA dimer, along the 2-fold rotation axis, showing the environment of the 
conserved tryptophan pair (residues W94 and W94’) and their close packing with neighbouring 
residues. The two subunits in the dimer are differently colored in magenta and cyan (oxygen 
atoms in red, nitrogen in blue, sulphur in yellow. Only residues of one subunit are labeled. 
(B) Similar stereo view as in A of the centre of a “closed” LmrR dimer, obtained via homology-
modeling using the 1XMA dimer as a template. Labels refer to the residues that are equivalent 




Figure S4 Spectroscopic control experiments. (A) Circular dichroism spectra of wild-type LmrR 
(solid line) and the LmrR-W67Y/W96Y double mutant (dashed line). (B) Fluorescence titration 
experiment of H33342 to a 0.4 mM solution of N-acetyl-tryptophanamide (NATA). The flat lines 
show the fluorescence spectra of the NATA solution after adding increasing amounts of H33342 
(final concentrations ranging from 100 to 700 nM). The upper green line shows the fluorescence 
spectrum after adding LmrR (to a final concentration of 0.2 mM as dimer) to the H33342/NATA 
solution at the end of the titration series. (C) Tryptophan fluorescence spectra recorded after 
titrating increasing amounts of daunomycin (final concentrations 200-800 nM) to a 0.4 mM 
NATA solution.



























































































































































































































































































































































































Figure S6 Stereo view of the three superimposed LmrR dimers (apo, H33342-bound and 
daunomycin-bound) docked to a 21 base-pair fragment of double-stranded B-form DNA. 
Docking was performed manually using the programs Coot (Emsley & Cowtan, 2004) and PyMOL 
(Delano Scientific). One of the two DNA recognition helices in each dimer (in the figure defined 
as the left one) could be optimally positioned in one of the two neighbouring major grooves 
of the DNA, but this resulted in a significant misalignment of the second DNA recognition helix 
with respect to the other major groove. The optimal location for the second DNA recognition 
helix that would allow the formation of binding interactions is indicated in dark magenta. Colors 
for the different LmrR structures are as follows: yellow, apo; green, H33342-bound; salmon, 
daunomycin-bound. The light and dark colors distinguish the two subunits in each dimer.
References
Zsila F, Bikadi Z, Simonyi M (2004) Induced circular dichroism spectra reveal binding of the 
antiinflammatory curcumin to human alpha1-acid glycoprotein. Bioorg Med Chem 12: 3239-
3245
Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D 
Biol Crystallogr 60: 2126-2132
Chapter 
Multidrug resistance regulator LmrR uses a single site  
to bind structurally diverse compounds
3
Pramod Kumar Madoori, Abhishek Tomar, Arnold J. M. Driessen and Andy-






LmrR is a PadR-like transcription factor in Lactococcus lactis that regulates the 
drug-induced expression of the ABC-type multidrug efflux transporter LmrCD. 
Previously, we reported crystal structures of LmrR in an unliganded state, and 
in complex with the cytotoxic compounds Hoechst 33342 and daunomycin. 
Here, we reveal two additional crystal structures of LmrR bound to the 
structurally diverse compounds ethidium and riboflavin. The new structures 
confirm that LmrR uses a single ligand-binding site within a large, symmetrical 
and hydrophobic pore in the dimer interface to accomplish multidrug binding. 
Multidrug recognition is dominated by the aromatic stacking interactions of 
Trp96/Trp96’ with the flat heterocyclic cores of the ligands. Additional drug 
binding stabilization is provided mainly by hydrophobic and van der Waals 
interactions with aliphatic amino acid residues. The hydrophilic ribityl moiety 
of riboflavin is less well accommodated within the hydrophobic binding 
site than the phenyl and ethyl moieties of ethidium, explaining the 20-fold 
lower binding affinity of the flavin compound. The measured binding affinity 
of riboflavin, a neutral ligand, was similar as the binding affinity measured 
previously for daunomycin, a cationic ligand, suggesting that electrostatic 
interactions with aspartate residues near the multidrug-binding site do not 
significantly contribute to ligand binding affinity. The use of a single site for 
binding the different ligands, rather than partially overlapping subsites, 
and the dominating role of the Trp96/Trp96’ pincer in drug recognition and 
binding, distinguishes LmrR from other well-characterized multidrug-linked 
transcription regulators.




When Lactococcus lactis is challenged with cytotoxic compounds like 
daunomycin, Hoechst 33342, ethidium and rhodamine 6G it readily displays 
a multidrug resistance (MDR) phenotype.1 The major factor responsible for 
eliminating these toxic compounds from the cell is the ABC efflux transporter 
LmrCD.2 Production of this transporter is controlled by the multidrug-sensitive 
transcriptional repressor LmrR.2, 3 In the absence of drugs, LmrR prevents 
expression of the transporter by binding to the lmrCD promoter. When 
toxic substrates enter the cell, their binding to LmrR triggers an allosteric 
response, resulting in its release from DNA followed by derepression of lmrCD 
transcription and subsequent increase in multidrug efflux activity. Through 
an autoregulatory mechanism LmrR also represses transcription of its own 
gene, ensuring a fine-tuned demand-dependent expression of the LmrCD 
transporter.4 
LmrR is a 116-residue protein that belongs to the PadR family of bacterial 
transcription regulators. Members of this large, but poorly characterized 
family have been implicated in the regulation of various adaptive responses 
in bacteria, leading to, for example, detoxification, MDR and virulence.5,6 
Apart from LmrR, LadR from Listeria monocytogenes is the only characterized 
member of the MDR-related PadR regulators.7 Crystallographic analysis of 
LmrR in its drug-free state, and in complex with the substrates Hoechst 33342 
(H33342) and daunomycin (DAU), has revealed the overall structural features 
of this protein and the location and architecture of its multidrug binding site.8 
LmrR forms a homodimer with each subunit containing a typical β-winged 
helix-turn-helix domain for DNA-binding, and a single C-terminal helix, which 
is responsible for dimerization. The overall structure of LmrR is reminiscent 
of that of members of the MarR/SlyA family of transcription factors,9,10 which 
regulate similar biological processes in bacteria, including antibiotic resistance 
and virulence, but which generally have a much larger C-terminal dimerization 
domain. A highly unusual feature of LmrR is the presence of a symmetrical, 
flat-shaped hydrophobic pore at the dimer centre that contains the multidrug-
binding site. H33342 and DAU bind in a similar manner with their aromatic 
rings sandwiched between the indole groups of two dimer-related tryptophan 




Multidrug-sensitive transcription regulators, like LmrR, are attractive 
targets for elucidating the mechanisms of multidrug recognition. They display 
similar substrate recognition profiles as the transporters they regulate, but, 
being soluble proteins, are more amenable to biochemical and structural 
studies. Our current understanding of multidrug binding and specificity by 
MDR-linked regulators is largely based on the crystallographic analysis of 
proteins belonging to the TetR and MerR family of transcription regulators, in 
particular QacR, TtgT, and BmrR.11-17 Although they recognize a similar range 
of ligands, with a preference for cationic lipophilic compounds containing 
planar aromatic groups, these proteins use different binding site designs 
and mechanisms to accomplish multidrug recognition.17,18 Unfortunately, the 
scope for getting insights into the mechanism of multidrug-recognition by 
LmrR, and how this mechanism relates to that used by QacR, TgtR and BmrR, 
is somewhat limited by the availability of only two structures of drug-bound 
LmrR complexes. Here we report two additional crystal structures of LmrR in 
complex with ethidium (ET) and riboflavin (RBF). The combined structural data 
of all four LmrR-drug complexes, together with solution-binding data, allows 
a better definition of the multidrug binding principles employed by LmrR, and 
demonstrates that its mechanism of multidrug recognition uniquely combines 
different features of other well-established multidrug binding models.
Materials and Methods
 
Crystallization and data collection
LmrR was produced as an untagged protein by nisin-induced overexpression 
in Lactococcus lactis and purified as described earlier.8 Complexes of LmrR with 
riboflavin and ethidium were prepared by mixing protein and drug in a 1:2 
molar ratio in a solution containing 20 mM Tris-HCl, pH 8.0, 280 mM NaCl and 
1 mM EDTA. Initial crystallization conditions were obtained by sparse-matrix 
screening, using the PACT and JCSG+ commercial kits (Molecular Dimensions) 
and a Douglas Instruments Oryx-6 crystallization robot. Manual optimization 
using a sitting-drop vapor diffusion setup resulted in a final and equivalent 
crystallization solution for both protein-ligand complexes, containing 0.1 
M Tris-HCl, pH 8.5, 17% PEG 2000 monomethyl ether (MME) and 0.2 M tri-
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methylamine N-oxide. Crystals grew overnight from drops containing 1 µl 
reservoir and 1 ml of the protein-drug mixture at 295 K. To allow flash-cooling 
of the crystals, a cryo-protecting solution was prepared from the reservoir 
solution by increasing the concentration of PEG 2000 MME to 40%. Addition 
of 0.1 M NaCl and 0.2 mM ligand to the cryoprotecting solution was necessary 
to sufficiently stabilize the crystals. X-ray intensity data were collected from 
single flash-cooled crystals on beamline ID23-2 at the European Synchrotron 
Radiation Facility (ESRF) at 100 K. Data were processed with MOSFLM19 or XDS20 
and scaled, merged, and reduced with programs from the CCP4 suit32 (http://
www.ccp4.ac.uk/).
Structure determination and refinement
Structures of LmrR complexes with riboflavin and ethidium were solved by 
molecular replacement with the program PHASER from the CCP4 program 
suite, using a single subunit of the unliganded LmrR dimer as a search model 
(PDB entry 3F8B). The models were improved in several cycles, by restrained 
refinement using the programs Phenix.refine21 and Refmac522, alternated 
by manual model building using COOT.23 Subsequently, the ligands were 
modeled into excess density observed in the central LmrR pore. Evaluation 
of the interaction geometries and real-space correlation factors was used 
to guide the docking of the ligands. Fixed translation libration screw (TLS) 
parameters were determined using the TLS motion detection server24 and then 
used in the subsequent rounds of structure refinement. In the last stages of the 
refinements, water molecules were placed and retained in the model by strict 
criteria of difference density, B-factor cutoffs, and hydrogen-bonding capacity. 
The quality of the final models was checked using MolProbity.25 Selected data 
collection and refinement statistics are presented in Table I. The coordinates 
and structure factors have been deposited in the RCSB with PDB accession 
codes 3UJY and 3UJ5 for LmrR•RBF and LmrR•ET, respectively.
Structure analysis
The surface and volume of the central pore were generated using 




complementarities were calculated using the programs Areaimol and Sc from 
the CCP4 program suite. Ligand interactions were identified both interactively 
using PyMOL27 and automatically using LIGPLOT.28




Space group P43212 P212121
Cell dimensions 
 a, b, c (Å)
 a,β,γ (°)






Resolution range* 35 -2.4 (2.53-2.4) 50 -2.00 (2.11-2.0)
No. of unique reflections 4872 19496
Completeness (%)* 98.8 (99.3) 99.4 (100.0)
Multiplicity* 3.3 (3.4) 4.0 (4.0)
Rmerge
* 0.057 (0.37) 0.082 (0.337)
I/σI* 15.3 (3.2) 11.5 (3.8)
Refinement
Resolution range 30-2.35 50-2.0
Rfactor/Rfree 0.21/0.27 0.20/0.26
No. of atoms in asymmetric unit, average B factor (Å2)
 Protein 809, 43.2 
(chain A)
1816, 27.4
(chains A and B) 
  Solvent 17, 32.4 100, 13.54 
 Ligand 54, 49 24, 45.8
Rmsd
 Bond lengths (Å) 0.01 0.022
 Bond angles (º) 1.01 1.74
Ramachandran analysis, validation
 Preferred regions (%) 100 97.3
 Allowed regions (%) 0.0 2.3
 Outliers (%) 0.0 0.0
 Molprobity score 1.5 1.5
PDB entry 3UJY 3UJ5
Rmerge = ; Rfactor = , for all measured reflections in the specified 
resolution range; Rfree = , for reflections belonging to a random test set not 
used in refinement (10% of the data).
*Values in parentheses refer to the highest resolution shell




Dissociation constants of RBF and ET were obtained from fluorescence 
titration experiments. The RBF titration experiment employed the change 
in intrinsic fluorescence of the ligand upon binding as described.29 The ET 
titration experiment employed the change in tryptophan fluorescence of 
LmrR upon ligand binding, following the same protocol as used previously 
for monitoring the binding of DAU.8 Samples were scanned three times to 
obtain the final fluorescence emission spectra. Spectra were corrected for 
background emission and dilution effects. Apparent dissociation constants of 
RBF and ET were obtained by data fitting using non-linear regression analysis 
(using the program SigmaPlot). The RBF binding assay was performed on a 
Spex Fluorolog 322 fluorescence spectrophotometer at 25 °C. To a 1-ml stirred 
cuvette with purified LmrR in binding buffer (20 mM Tris–HCl, pH 8.0, 150 mM 
NaCl and 1 mM EDTA, dimer concentration of 1.5 mM), RBF was added in 2 ml 
steps. RBF fluorescence was measured after each titration step. For reference, 
RBF was also titrated to the buffer solution without protein. The excitation 
and emission wavelength were 435 and 523 nm, respectively. Tryptophan 
fluorescence for the ET binding assay was recorded at room temperature with 
an Aminco Bowman Series 2 spectrophotometer, using a 0.2 ml cuvette and an 
excitation wavelength of 295 nm. ET was added in 2 ml steps to 0.1 mM purified 
LmrR (dimeric concentration). Emission spectra were obtained from 300 to 




Structures of LmrR, in complex with RBF (LmrR•RBF) and ET (LmrR•ET), were 
solved by molecular replacement and refined at 2.35 Å and 2.0 Å, respectively. 
The LmrR•RBF structure has the same crystal form (space group P43212) as the 
previously determined structure of LmrR bound to H33342 (LmrR•H33342), 
with a single protein subunit occupying the asymmetric unit and the 2-fold 




LmrR•ET structure has a different crystal form (space group P212121), with a 
full LmrR dimer occupying the asymmetric unit, which is identical to that of 
the previously determined structure of LmrR bound to DAU (LmrRŸDAU).8 
Data statistics, refinement details and model content of the two structures 
are summarized in Table 1. There is well-defined electron density for the 
polypeptide chains, except for the tip region of the β-wings (residues 70-75) 
and the N- and C-termini (residues 1-5 and 109-116), which show a high degree 
of disorder, especially in the LmrR•RBF structure. Amino acid residues with no 
observed electron density were excluded from the final models. The X-ray 
data clearly confirms the presence of the bound ligands in the central drug-
Figure 1. LmrR ligands. (A) Chemical structures of riboflavin (RBF), ethidium (ET), Hoechst 33342 
(H33342) and daunomycin (DAU). (B) 2Fo-Fc electron density for RBF in the LmrR•RBF structure 
calculated at 2.0 Å resolution and contoured at 1σ. The two crystallographically independent 
binding conformations of RBF are shown in stick representation with the carbon atoms colored 
green or cyan (oxygen and nitrogen atoms are colored red and blue, respectively). These binding 
conformations differ by a ~180° rotation of the heterocyclic isoalloxazine core relative to the 
ribityl moiety. The other two binding modes of RBF (shown with dark green lines) are related 
to the first two by 2-fold crystallographic symmetry (the location of the crystallographic dyad is 
indicated with an arrow). (C) 2Fo-Fc electron density for ET in the LmrR•ET structure, calculated 
at 2.4 Å resolution and contoured at 1σ. The ligand is shown in stick representation with carbon, 
oxygen, nitrogen atoms colored yellow, red and blue, respectively.
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binding pore of LmrR (Figures 1 and 2). Electron density for the heterocylic 
aromatic core and ethyl substituent of ethidium molecule is well defined, but 
its phenyl substituent shows less defined density, indicative of some degree 
of rotational mobility (Figure 1B). Docking of RBF was more complicated since 
the electron density of the ligand in the LmrR•RBF structure is averaged by the 
occurrence of four mutually exclusive binding modes (Figure 1C). Two binding 
modes of RBF are related by a conformational change in the ligand, involving 
a ~180° flip of the heterocyclic isoalloxazine moiety relative to the ribityl side 
chain. In addition, each of these two binding modes has a crystallographic 
symmetry equivalent, due to the symmetrical position of the ligand-binding 
site in LmrR•RBF on the crystallographic dyad. With the four binding modes 
superimposed, the isoalloxazine moiety of RBF shows a good fit to the 
averaged density, but the ribityl side chain is less well defined. Since the four 
binding modes are highly similar, we will describe only one in detail in the rest 
of this paper.
Ligand binding and recognition
The overall binding modes of ET and RBF are similar to those of H33342 and 
DAU in the previously determined LmrR-ligand structures (Figures 2 and 3).8 
The flat aromatic cores of the ligands slide into the centre of the flat-shaped 
hydrophobic pore of the LmrR dimer, while the more bulky ring substituents 
protrude towards the pore opening. Drug recognition by LmrR is dominated 
by the aromatic stacking interactions of the Trp96/Trp96’ indole pair with the 
heterocylic aromatic cores of the ligands. Further stabilization is provided 
by apolar contacts of the ligands with hydrophobic amino acid residues in 
helices a1, a4, a1’ and a4’, which face the drug binding pore and surround 
the central Trp96/Trp96’ pair. With a total pore volume of ~1200 Å3 and ligand 
volumes of 300-400 Å3, it is evident that the ligands occupy only a fraction of 
the volume that is available in the central pore (Figure 2C). The hydrophobic 
interior of the pore prohibits formation of H-bonds between protein and polar 
atoms in the cores of the ligands. However, while wedged inside the pore, 
polar atoms at the edges of the heterocyclic rings systems are accessible to 
solvent, and a few localized solvent molecules contribute to drug binding 
stabilization. Noteworthy, all protein residues in close vicinity of the ligands 




Asp100 contributes to the stabilization of the hydrophilic ribityl moiety of the 
ligand, possibly by the formation of hydrogen bonds, although the observed 
disorder of the ribityl moiety indicates that these interactions are quite weak. A 
similar situation occurs in LmrR•DAU, where Asp100 is found near to the amino 
sugar substituent of DAU, but does not form strong directive interactions, 
e.g. hydrogen bonds, as indicated by the high disorder of the substituent.8 In 
Figure 2. Overall structures of the LmrR-ligand complexes. (A) Top view of the LmrR•RBF dimer 
in cartoon representation, showing the central pore accessible surface (in grey) and a bound 
RBF (in green) stacked in between the W96/W96’ residues. For clarity, only one of the four RBF 
binding modes is shown. An overlay of bound ET (in yellow) is added, based on a superposition 
of the LmrR•ET and LmrR•RBF structures. The two chains of the LmrR dimer are colored brown 
and grey, and the secondary structure elements are labeled. (B) Side view of the LmrR•RBF dimer, 
showing accessible surface for the central pore, bound RBF, and an overlay of bound ET from the 
LmrR•ET structure. (C) Overlays of bound RBF (carbon atoms colored green), ET (yellow), DAU 
(cyan) and H33342 (magenta) in the central pore of LmrR. The positions of the ligands are based 
on superpositions of the different ligand-bound LmrR structures. The pore surface is calculated 
from the LmrR•RBF structure. Oxygen and nitrogen atoms are colored red and blue, respectively.
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LmrR•ET the carboxylate groups of Asp100 (and its dimer-related equivalent 
Asp100’) are at ~8 Å distance from the positively charged quaternary amine 
of ethidium, indicating that long-range electrostatic effects may contribute to 
ligand binding.
Ligand binding and recognition were further analyzed by calculation 
of the buried accessible surface areas (ASA) and the ligand/binding site 
shape complementarities of the four structurally characterized LmrR-ligand 
complexes (Table 2). 






















565 (494/71) 476 (442/34) 78 0.68
DAU 0.24
(±0.05)‡
506 (333/173) 440 (349/91) 72 0.73
† In parenthesis are the contributions from apolar/polar atoms
‡ KD values for H33342 and DAU are taken from Madoori et al.
8
In addition, the dissociation constants (Kd) of RBF and ET were determined by 
fluorescence-based binding assays, and compared to those derived previously 
for H33342 and DAU (Figure 4 and Table 2). The results reveal similar ligand ASA 
burial (75 ± 3%) and ligand/binding site shape complementarity (0.73 ± 0.04) 
for the four different LmrR-ligand complexes. The shape complementarities 
are similar to those observed in ligand-bound complexes of other multidrug 
binding transcription regulators,17 but the ligand ASA burial values are lower, 
consistent with the more open environment of the drug binding pore in LmrR. 
The measured Kd values (Figure 4) reveal a strong binding affinity of LmrR for the 
different ligands. ET shows the tightest binding (Kd = 11 ± 2 nM), comparable 
to that of H33342, while RBF, like DAU, shows an approximately 20-fold lower 




H33342 versus RBF and DAU are not explained by differences in total ligand 
ASA burial, but there is a clear correlation between ligand binding affinity and 
amount of hydrophobic versus hydrophilic ASA buried by the protein upon 
binding the ligands. For LmrR•ET and LmrR•H33342, over 80-87 % of the total 
buried surface of the ligand is hydrophobic, compared to 55-66 % for LmrR•RBF 
and LmrR•DAU. These differences arise from the hydrophilic ribityl and amino 
sugar substituents in RBF and DAU, respectively, and are indicative of the 
penalty paid by accommodating these substituents inside the hydrophobic 
drug-binding pore. 
Figure 3. Close-up views of the multidrug binding site and ligand-interacting residues of (A) 
LmrR•RBF, (B) LmrR•ET, (C) LmrR•H33342 and (D) LmrR•DAU. Amino acid residues within a radius 
of 4.5 Å from a ligand are shown in stick representation and labeled. Colors as in Figure 2. Water 
molecules within 3.5 Å from a ligand are shown as red spheres.
Figure 4. Fluorescence titration curves measuring RBF and ET binding to LmrR.
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Conformational flexibility of LmrR
Comparison of the LmrR•RBF and LmrR•ET structures reveals minimal 
differences in side chain conformations at the ligand-binding site. However, as 
noted previously for the LmrR•H33342 and LmrR•DAU structures,8 the LmrR•RBF 
and LmrR•ET dimers show significant differences in helix orientations, affecting 
the size and shape of the central ligand binding pore, as well as of the DNA 
binding site (Figures 3 and 5A). Compared to LmrR•RBF, helices a4 and a4’ in 
LmrR-ET have rotated outwards, away from the dimer centre, by ~10° while 
helices a1 and a1’ have rotated inwards by 8°. As a result the mouth of the 
central pore is somewhat more open in the ET-bound LmrR dimer, allowing 
Figure 5. Conformational differences between the drug-bound structures of LmrR. (A) Pairwise 
superpositions of the four drug-bound dimers. The positions of the DNA recognition helices 
(a3, a3’) are emphasized by dashed lines. (B) Superposition of the single subunits of the four 
drug-bound LmrR structures in two different views, related by a 90° rotation. For the asymmetric 
LmrR•ET and LmrR•DAU dimers both subunits are included in the superposition. The two hinge 
regions are indicated by arrows and the ranges by which the orientations of helices a1 and 
a4 differ are shown. The coloring is as follows: subunit A and B of LmrR•ET, yellow and orange; 
subunit A and B of LmrR•DAU, light and dark blue, subunit A or B of LmrR•RBF, green; subunit A 




a better accommodation of the ligand’s phenyl group. The movement of the 
a1, a1’, a4 and a4’ helices is further coupled to an inward rotation of the core 
of the wHTH domains by ~17°, including helices a3 and a3’, shortening the 
distance between the centres of the DNA-binding helices from 31 Å to 27 Å. 
A superposition of the individual subunits of the different ligand-bound LmrR 
dimers reveals that the conformational flexibility largely originates from two 
hinge regions in the polypeptide chain of LmrR: in the a1-a2 loop and in the 
loop that connects a4 to the β-wing (Figure 5B). Differences in backbone 
conformations at the hinge regions affect the orientations of helices a1 and 
a4 relative to the core of the wHTH-domain. Significant differences in the 
relative orientations of helices a1 and a4 are also observed between the two 
subunits of the LmrR•ET and LmrR•DAU dimers, consistent with the presence 
of asymmetric dimers in the crystal with a ligand bound in a single dominant 
configuration.
Since LmrR-RBF and LmrR-ET crystallized in different crystal forms, it is 
possible that the observed conformational change is caused by differences in 
the crystal packing geometry. Indeed, pairwise comparison of the RBF-bound 
versus H33342-bound and ET-bound versus DAU-bound structures, which 
share the same crystal forms, reveals smaller conformational differences (Figure 
5A). In particular, the overall structures of the LmrR•ET and LmrR•DAU dimers 
are highly similar. On the other hand, the LmrR•RBF and LmrR•H33342 dimers 
still reveal significant reorientations of the a-helices at the ligand and DNA 
binding sites, indicating that drug-specific interactions at the drug binding site 
of LmrR, at least to some extent, directly influence the dimeric conformational 
changes. 
Discussion
The new LmrR•ET and LmrR•RBF structures, and their comparison with the 
previously determined structures of LmrR bound with H33342 and DAU, confirm 
that LmrR contains a single ligand-binding site within its large symmetrical 
flat-shaped pore, and employs a common set of almost exclusively apolar 
residues to achieve multidrug binding. Conformational flexibility is important 
for the function of LmrR as a multidrug-induced transcription regulator. The 
ligand-bound LmrR dimers show different conformations, affecting the overall 
geometries of both the drug and DNA binding sites.  In particular, the overall 
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flexibility is associated with a change in mutual distance and inclination of the 
two DNA recognition helices, which likely affects their ability to simultaneously 
insert into two neighboring major grooves on the DNA.8 This indicates that 
the observed flexibility and conformational coupling of the drug and DNA 
binding sites play a role in the drug-based induction mechanism of LmrR. A 
similar allosteric cross-talk, in which drug binding is coupled to a change in the 
mutual distance and inclination of the two DNA recognition helices, has been 
observed for other multidrug binding transcriptional regulators, although the 
conformational changes underlying the allosteric coupling differ significantly.11 
To which extent the changes affect the binding of LmrR to DNA cannot be 
validated due to lack of structural information of the LmrR•DNA complex. 
The “common-site” multidrug binding mechanism of LmrR differs 
significantly from the canonical “multisite” model, as presented by QacR, in 
which multi-faceted ligand recognition is facilitated by a series of overlapping 
“mini-pockets” within a large drug binding site.11 The common binding mode 
of the different ligands in the central pore of LmrR is largely dictated by the 
symmetry-related Trp96/Trp96’ pair, which acts as an anchoring point and 
selectivity filter, due to its ability to form strong aromatic stacking interactions 
with the flat heterocyclic cores of the ligands. Promiscuous drug binding is 
realized by directing the groups of different chemistries and sizes towards the 
opening of the pore, where they are more solvent-exposed. The use of two 
subsites, one for interacting strongly with the planar and hydrophobic groups 
of the ligands, serving as a common anchoring point, while another, more 
solvent-exposed subsite accommodates the variable groups of the ligands, 
is reminiscent of the alternative multidrug-recognition model displayed by 
BmrR.17, 18 However, the symmetrical location of the multidrug binding site 
within a large and flexible pore, and the unique disposition and role of the 
Trp96/Trp96’ pair, significantly differentiate LmrR from BmrR, which uses a 
non-symmetrical drug binding pocket that is relatively small and rigid. 
Another striking difference of LmrR with other characterized MD-linked 
transcription regulators like QacR and BmrR is the absence of polar or charged 
residues at the drug-binding site. Multidrug recognition is rarely devoid of 
polar contributions, even though they conflict with the necessity of a multidrug 
binding protein to avoid interactions displaying high specificity. MD-linked 
transcription regulators like QacR and BmrR use a limited set of polar residues 




ligands, and, in particular, binding of cationic lipophilic drugs is stabilized by 
short-range electrostatic interactions with buried acidic residues.11, 16, 17, 30 It 
should also be noted, though, that the interactions with acidic residues are 
not always critical for binding the cationic ligands as recently revealed for 
QacR.31 In LmrR, Asp100 and its dimer-related counterpart Asp100’ are too 
far from the drug binding site to allow short-range electrostatic interactions, 
although long-range electrostatic interactions could contribute to binding of 
the lipophilic cationic drugs, explaining the tight binding of ET and H33342. 
On the other hand, the similar Kd’s of RBF and DAU, a neutral and positively 
charged molecule, respectively, indicate that electrostatic interactions with 
Asp100 are not a major discriminating factor in drug binding by LmrR. Rather, 
together with the aromatic stacking interactions of the Trp96/Trp96’ pair, 
burial of hydrophobic surface appears to be the key component of multidrug 
recognition in LmrR. This is evident from the correlation between ligand 
binding affinity and amount of hydrophobic versus hydrophilic ASA buried by 
the protein upon binding the ligands. The weaker binding ligands RBF and DAU 
show a significantly smaller burial of hydrophobic versus hydrophilic burial than 
ET and H33342, due to the presence of their hydrophilic substituents. It should 
be noted, though, that, on average, the observed ligand binding affinities for 
LmrR are significantly higher than those reported for other multidrug binding 
transcriptional regulators, for which ligand Kd values usually fall in the 1-100 mM 
range. How does LmrR manage to obtain such a tight binding in the absence 
of polar residues at its drug-binding site? Most likely, lack of polar amino acids 
is compensated by the central location of the drug-binding site within a large 
pore, allowing easy access for solvent to the ligands from all directions within 
the plane of the pore. In this way, LmrR avoids a large desolvation penalty for 
transfer of polar groups to the hydrophobic binding site. By comparison, in 
multidrug binding proteins like QacR and BmrR the ligand binding pockets are 
more occluded from solvent, necessitating the use of polar and charged amino 
acid residues to avoid large destabilizing effects from burying the hydrophilic 
groups of the ligands. 
In conclusion, our structural studies have elucidated key features of 
multidrug recognition in LmrR, which, in its essence, represents a unique 
combination of the mechanistic features of multidrug binding exhibited by 
other MDR-linked regulators. Like QacR, LmrR has the availability of a large and 
flexible region for ligand binding, but unlike QacR and like BmrR, it employs 
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a single set of strong aromatic interactions to anchor the structurally and 
chemically diverse compounds to a common ligand binding subsite, rather 
than different sets of hydrophobic and hydrophilic residues defining partially 
overlapping subsites. The nature of this common ligand binding subsite, with 
a symmetry-related tryptophan pair to firmly grab the flat, aromatic rings of 
the ligands, is a unique feature of LmrR, as is the absence of polar and charged 
residues in its multidrug binding site. Although difficult to quantify, water 
molecules must play a significant role in multidrug binding by LmrR, via their 
ability to form H-bonds with polar atoms of the ligands, and by decreasing 
the free energy of ligand binding due to the entropy gain associated with 
their release from the protein-drug hydrophobic interface. Whether distantly 
located acidic residues in LmrR are important to stabilize the cationic lipophilic 
ligands is still unclear. This, and the precise mechanism by which multidrug 
binding in LmrR affects DNA binding, are subjects of future investigations.
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The lytic transglycosylase MltF from Escherichia coli is an outer membrane-
bound, periplasmic protein with two domains, a C-terminal catalytic domain 
with a lysozyme-like fold and an N-terminal domain of unknown function that 
is homologous to periplasmic substrate-binding proteins of ABC transporters. 
To investigate its structure and function, a soluble form of full length MltF 
(sMltF), containing both domains, and a soluble fragment containing only 
its N-terminal domain (sMltF-NTD), were purified and crystallized. Crystals of 
sMltF belonged to space group P43212 or P41212, with unit-cell dimensions a = 
b = 110.8 Å, c = 163.5 Å and two molecules per asymmetric unit. A complete 
data set was collected to 3.5 Å resolution. Crystals of sMltF-NTD belonged to 
space group P3121 with unit-cell parameters a = b = 82.4 Å, c = 75.2 Å and 
one molecule per asymmetric unit. For sMltF-NTD a complete native data set 
was collected to 2.20 Å resolution. In addition, for phasing purposes a three-
wavelength MAD data set was collected to 2.5 Å resolution using a bromide-
soaked sMltF-NTD crystal. Using phases derived from the Br-MAD data it was 





The viability and shape of bacteria depends on the presence of an intact cell 
wall that surrounds their cytoplasmic membrane. The integral component 
of the bacterial cell wall is a heteropolymer known as peptidoglycan (PG) 
or murein. It is composed of glycan strands of alternatingly β-1,4-linked 
N-acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc) residues, 
cross-linked by peptides that are connected to the lactyl groups of the MurNAc 
residues (Vollmer et al., 2008). The mesh-like PG structure gives the cell wall 
its mechanical strength, allowing bacterial cells to withstand the high internal 
osmotic pressure. Once synthesized, however, the PG polymer is not a static 
macromolecule, but it is subject to continuous remodeling and turnover (Park 
& Uehara, 2008). In particular, PG cleavage is required to create space for the 
insertion of new material and to recycle old material during cell growth, to 
incise the cell wall during cell division, and to create local openings in the 
cell wall for allowing the insertion of various cell envelop spanning structures 
(Holtje, 1998, Koraimann, 2003, Scheurwater et al., 2008). PG cleavage is 
carried out by bacterial glycolytic and peptidolytic enzymes that are referred 
to as autolysins. Some of these bacterial enzymes are crucial for bacterial 
pathogenicity and have been shown to modulate muropeptide release and/or 
host innate immune responses (Lee et al., 2009).
Lytic transglycosylases (LTs) form one set of autolysins, that target the 
β-1,4-linkages between the MurNAc and GlcNAc residues of PG (Höltje, 1996, 
Scheurwater et al., 2008). They act like lysozymes, and other β-1,4-glycosyl 
hydrolases, but differ with respect to the reaction products. Strictly speaking, 
LTs are glycosyl transferases, and not hydrolases, which combine cleavage 
of an inter-residue β-1,4-glycosidic bond with formation of an intra-residue 
1,6-glycosidic bond, thereby producing GlcNAc-anhydro-muropeptides 
(Figure 1). LTs are ubiquitous among all eubacteria that produce PG, but the 
complement of enzymes produced by Escherichia coli has been the most 
extensively examined. E. coli is known to produce six outer membrane-bound 
lytic transglycosylases (MltA, MltB, MltC, MltD, MltE, MltF) and one soluble 
lytic transglycosylase (Slt70) (for reviews see (Höltje, 1996, Scheurwater et 
al., 2008)). Most appear to act as exo-enzymes releasing GlcNAc-anhydro-
muropeptides from the ends of glycan strands, except for MltE, which has been 




the archetypes for three of the four families of LTs identified by Blackburn and 
Clarke (Blackburn & Clarke, 2001). Crystal structures, complemented with sugar 
and muropeptide binding studies, have been reported for Slt70 (Thunnissen 
et al., 1994, van Asselt, Thunnissen et al., 1999), MltA (van Straaten et al., 2007, 
van Straaten et al., 2005) and Slt35 (a soluble proteolytic fragment of MltB (van 
Asselt, Dijkstra et al., 1999, van Asselt et al., 2000), representing LT families I, 
II and III, respectively. These crystallographic studies allowed a thorough 
understanding of the structures and catalytic mechanism of LTs, and revealed 
that most of these enzymes, with the exception of MltA, share a catalytic 
domain that resembles the fold of goose-type lysozyme (Thunnissen et al., 
1995). However, the specific roles of the different E. coli LTs in PG metabolism 
has remained unclear (Heidrich et al., 2002), which is emphasized by the notion 
that most LTs contain additional, non-catalytic domains for which the function 
is often unknown.
MltF from E. coli is a recently characterized member of LT family I, 
which, based on sequence analysis and functional assays, contains a typical 
lysozyme-like C-terminal domain (hereafter named the LT domain) that is 
responsible for the LT activity (Scheurwater & Clarke, 2008). As a unique feature, 
however, it contains an N-terminal domain that is homologous to periplasmic 
substrate-binding proteins of ABC transporters, in particular to those specific 
for histidine, lysine-arginine-ornithine (LAO) and glutamine (Tam & Saier, 
1993). The function of this N-terminal domain (MltF-NTD) is unknown. No 
peptidoglycan binding activity could be measured for MltF-NTD, nor have any 
ligands been identified that may form substrates of this domain (Scheurwater & 
Clarke, 2008). The N-terminal domain was shown to modulate the lytic activity 
of the LT domain, to permit continued lysis of insoluble peptidoglycan at a 
Figure 1. LTs catalyze the cleavage of the β-1,4-glycosidic bond between MurNAc and GlcNAc 





constant rate (Scheurwater & Clarke, 2008), but how this modulation happens 
is currently not  understood. 
To obtain insights in the role of the N-terminal domain of MltF, and 
how it may affect the catalytic function of the LT domain, we study MltF using 
X-ray crystallographic and biochemical methods. In this paper we describe 
the purification, crystallization and preliminary X-ray analysis of two soluble, 
C-terminally His6-tagged forms of MltF lacking residues 1-22, one containing 
both domains (sMltF) and one containing only the N-terminal domain (sMltF-
NTD).
2. Materials and methods
2.1 expression and purification
Soluble MltF (sMltF, 511 residues), lacking the predicted signal sequence and 
transmembrane helix (residues 1-22) but with an extra C-terminal H6-tag, 
was expressed using the previously published expression vector pACES-8 
(Scheurwater & Clarke, 2008). Expression was carried out in the E. coli strain 
Rosetta 2 (DE3) pLysS (Novagen). A 2 liter LB culture, supplemented with 
chloramphenicol (34 μg ml-1) and kanamycin (50 μg ml-1) was incubated at 310 
K until the OD600nm reached ~0.6. The cells were then induced by the addition 
of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubated for an 
additional 3 hours at 310 K. For the preparation of soluble fractions, cultured 
cells were harvested by centrifugation at 6000g for 20 min at 277 K and 
the resulting bacterial pellet was resuspended in 50 ml ice-cold lysis buffer 
containing 20 mM Tris–HCl, pH 8.0, 300 mM NaCl, 2 mM imidazole, 0.2% NP40, 
1 mM β-mercaptoethanol, and appropriate amounts of DNase, RNase and 
protease inhibitors (Roche Applied Science). Cells were lysed using a French 
press, and the soluble proteins were collected by centrifugation at 6000g for 20 
min at 277 K. The supernatant was applied to a 0.5 ml Ni-NTA (Qiagen) column 
pre-equilibrated with 20 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM imidazole 
and 1 mM β-mercaptoethanol (buffer A). The column was washed with 3-4 
column volumes of buffer A to remove unbound proteins and sMltF was 
eluted with 200 mM imidazole in buffer A. Elution fractions containing sMltF 




mM dithiothreitol (DTT)) and subsequently loaded onto a monoQ column (GE 
Healthcare), which was equilibrated with buffer B. Elution was carried out with 
a gradient of NaCl concentrations increasing from 50 mM to 500 mM. The peak 
fractions containing sMltF were pooled and concentrated to 12 mg ml-1 in 20 
mM Tris-HCl, pH 8.0, 50 mM NaCl, 1 mM EDTA and 1 mM DTT, using an Amicon 
ultrafiltration centrifugal device (Millipore).
Expression and purification of the N-terminal domain of sMltF (sMltF-
NTD, residues 23-270 with additional C-terminal H6-tag) followed a similar 
procedure as used for the full length protein. Expression was carried out with 
the vector pACES-13 (Scheurwater & Clarke, 2008) in C43 (DE3) E. coli cells, using 
LB media supplemented with kanamycin. A three-step purification protocol, 
using Ni-NTA, monoQ and gel filtration chromatography, was applied to obtain 
pure protein. The Ni-NTA and monoQ purification steps were performed as for 
sMltF. Gel filtration was carried out on a Superdex 200 column (GE Healthcare) 
pre-equilibrated with column buffer containing 50 mM Tris-HCl, pH 8, 50 mM 
NaCl and 1 mM DTT. The peak fractions containing sMltF-NTD were pooled and 
concentrated to 6 mg ml-1 in gel filtration column buffer. Protein concentrations 
were estimated from the absorbance at 280nm (A280) using theoretical molar 
extinction coefficients of 84230 M-1 cm-1 and 38390  M-1 cm-1 for sMltF and for 
sMltF-NTD, respectively.
All purification steps were performed at 280 K and the results of each 
step were monitored by SDS–PAGE. The finally obtained protein samples were 
highly pure (>98%) and mono-disperse, as judged from silver-stained SDS-PAGE 
gels and dynamic light scattering experiments (DynaPro, Wyatt Technology), 
respectively. After concentration the protein samples were quickly frozen in 
liquid nitrogen or used immediately for crystallization screening.
2.2 Crystallization
Screening for initial crystallization conditions was performed using the 
sitting-drop vapour-diffusion method, with the aid of an Oryx-6 crystallization 
robot (Douglas Instruments) at 298K and using the commercial JCSG+ and 
PACT crystallization screens (Molecular Dimensions Ltd). Lead conditions 
for crystallization were further optimized by changing salt concentration, 
precipitant concentration, temperature, and by changing the buffering agents. 




hanging-drop vapour-diffusion method, by mixing and equilibrating equal 
volumes (1 μl) of the protein and reservoir solutions against 500 μl reservoir 
solutions in a 24-well plate. Tetragonal crystals of sMltF measuring 80 × 40 × 20 
μm3 were grown from 0.1 M NH4-acetate, 0.1 M bis-Tris, pH 5.5, 15 % PEG 10000. 
Trigonal crystals of sMltF-NTD having dimensions of 200 × 60 × 60 μm3 were 
grown from 0.15 M Li2SO4, 0.1 M Na citrate, pH 5.5, 20% PEG 3350. 
2.3 X-ray data collection and processing
X-ray diffraction data were collected at the ESRF, Grenoble, using cryo-cooled 
crystals. Full-length sMltF crystals were cryo-protected by increasing the 
PEG 10000 concentration to 30 %. Cryo-protection of the sMltF-NTD crystals 
required the addition of 15 % glycerol to the crystallization solution. Data were 
integrated using XDS (Kabsch, 1993), and scaled and merged to unique data 
sets with the programs SCALA and TRUNCATE from the CCP4 suite (Win, et al., 
2011). The sMltF crystals suffered from extensive radiation damage, resulting in 
a somewhat poor overall quality of the data set and a useful resolution of only 
3.5 Å, even though diffraction extended to about 2.5 Å at the beginning of the 
data collection experiment. The sMltF-NTD crystals, on the other hand, were 
very stable in the X-ray beam and diffracted to 2.2 Å resolution. In addition 
to a native data set, a three-wavelength Br-MAD data set was collected from 
a single MltF-NTD crystal, that was soaked for 15-20 seconds in a solution 
containing 20% glycerol and 0.6 M NaBr just prior to freezing, following 
published protocols (Dauter et al., 2000) . Tables 1 and 2 list the relevant data 
collection statistics. 
3. Results and discussion
Both full-length sMltF and sMltF-NTD were successfully purified and 
crystallized. X-ray data were collected on cryo-cooled crystals using the MX 
beam lines at the ESRF, Grenoble. Crystals of sMltF diffracted to a maximum 
resolution of 2.5 Å, but due to radiation damage the finally obtained unique 
data set was complete only up to 3.5 Å resolution (Table 1). The space group 
was identified as P43212 or P41212, with unit cell dimensions a = b = 110.8 




asymmetric unit contains either one protein molecule (Matthews coefficient 
of 4.4 Å3 Da-1) or two protein molecules (Matthews coefficient of 2.2 Å3 Da-1), 
with a solvent content of 72% or 44% respectively. A Patterson self-rotation 
map did not reveal the presence of any rotational noncrystallographic 
symmetry (NCS), nor was any translational NCS detected in a native Patterson 
map, indicating that the asymmetric unit probably contains a single protein 
molecule. In solution, sMltF behaves as a monomer based on gel-filtration 
chromatography and static light-scattering analysis (not shown). It cannot be 
excluded, however that an NCS peak that is present in the self-rotation map 
is obscured by a crystallographic symmetry-axis peak. Crystals of sMltF-NTD 
allowed the collection of a complete data set to 2.2 Å resolution (Table 2; Fig. 
2b). 
Based on these data, the space group of the sMltF-NTD crystals was initially 
determined to be P3121 or P3221, with unit cell dimensions a = b = 82.4 Å, c 
= 75.2 Å and a single molecule per asymmetric unit (solvent content 51 %). 
Figure 2. Diffraction images of sMltF 
crystals from (a) full-length protein and 
(b) sMltF-NTD. The edge of the detector 
corresponds to 1.8 Å and 1.7 Å for (a) and 
(b), respectively. Insets display the quality 




Molecular replacement was tried as a method to obtain initial phases for the 
sMltF and sMltF-NTD diffraction data, using search models based on the LT 
domain of Slt70 and on various structures of periplasmic substrate-binding 
proteins, but without success. However, in an alternative approach to obtain 
phases, a three-wavelength MAD data set was collected to 2.5 Å resolution 
of a single bromide-soaked crystal of sMltF-NTD (Table 2). Phase calculation 
and refinement were performed for both space groups (P3121 or P3221) using 
the program SHARP/autoSHARP (Vonrhein et al., 2007), followed by density 
modification with SOLOMON (Abrahams & Leslie, 1996). Three different 
bromide sites were identified in the asymmetric unit and the best set of phases 
was calculated using the space group P3121. The overall figure-of-merit (FOM) 
was 0.43 and 0.90 before and after solvent flipping, respectively, for reflections 
in the resolution range between 71.7 Å and 3.0 Å. The resulting experimental 
electron density map showed clear solvent-protein boundaries and in the 
table 1. Summary of the X-ray data collection for full-length sMltF. Values in parentheses are for 
the highest resolution shell.
Beam line ID23-2
Space group P43212 or P41212
Wavelength (Å)




Solvent content (%) 44.4
Resolution range (Å) 49.5-3.5
Total number of observations 55062 (7923)
No. unique reflections 12980 (1864)
Multiplicity 4.2 (4.3)
Completeness (%) 97.2 (98.0)
Rmerge
§
 (%) 12.3 (21.5)
Mean I/s(I) 8.6 (5.9)
§Rmerge = �hkl �i |Ii(hkl) – <I(hkl)>| / �hkl �i Ii(hkl) , where Ii(hkl) is the ith observation of reflection hkl 




protein-associated densities the features of secondary structural elements 
were clearly visible. Using automated-model building (Terwilliger, 2003) it was 
possible to fit a partial model of nearly 137 amino-acids (52 % of the complete 
protein) in the electron map. Further model building and refinement of the 
sMltF-NTD structure is in progress and will be reported elsewhere. In addition, 
crystallization conditions of full-length sMltF are currently being optimized in 
order to obtain better quality crystals. 




Beam line ID29 ID29
Space group P3121 P3121







Wavelength (Å) 0.9300 0.9198 0.9206 0.8569
Resolution range (Å) 71.4-2.2 41.4-2.6 41.3-2.7 41.4-2.8
Unique reflections 15240 9004 8503 7526
Multiplicity 7.0 8.0 8.0 8.0
Completeness (%) 100 (98.3) 100 (98.5) 100 (99) 100 (99)
Rmerge
§ (%) 5.5 (47.0) 8.0 (48.1) 10.6 (64.0) 9.5 (53.0)
Mean I/s(I) 19.1 (4.2) 20.5 (4.6) 17.0 (3.5) 18.2 (4.2)
§Rmerge = �hkl �i |Ii(hkl) – <I(hkl)>| / �hkl �i Ii(hkl) , where Ii(hkl) is the ith observation of reflection hkl 
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The lytic transglycosylase MltF from Escherichia coli contains, in addition 
to a C-terminal lysozyme-like catalytic domain, an N-terminal domain that 
is homologous to periplasmic substrate-binding proteins (SBPs) of ABC 
transporters. Neither the functional role nor the ligand binding characteristics 
of the SBP-like N-terminal domain are known. Here we report the structure of 
the N-terminal domain of MltF (MltF-NTD) solved by X-ray crystallography at 
2.2 Å resolution. Its bilobal architecture, the topology of the central β-sheets 
in its two subdomains and the structure of its inter-subdomain linkers define 
MltF-NTD as a type-2 SBP. The domain is particularly similar to periplasmic 
SBPs that bind polar and charged amino acids, although the sequence identity 
is low (15-24%). The structure has an open conformation and no bound ligand 
present at the inter-subdomain cleft. A comparison with the “ligand-closed” 
structures of the glutamine-binding, the lysine/arginine/ornithine-binding 
and histidine-binding proteins revealed that two of the residues that bind 
the a-ammonium and a-carboxylate groups of the ligand in the amino-acid-
binding proteins are conserved in MltF-NTD (Arg125 and Asp203). However, 
there are also important differences in side chain composition and local 
polypeptide conformations at the inter-subdomain cleft, indicating that MltF-
NTD has significantly different ligand binding characteristics as its structural 
homologs.




Substrate-binding proteins (SBPs) form a wide-spread superfamily of proteins 
and domains, which are found in all three kingdoms of life and function as 
receptors in signal transduction, regulation and solute transport.1-7 Despite 
their low overall sequence identities and large variation in sizes, SBPs share 
a highly similar overall fold, consisting of two structurally conserved a/β 
domains, that are connected by a hinge region and that form a deep cleft at 
their interface for substrate binding.6 Hinge-bending movements lead to 
closure of the substrate-binding site, thereby burying a bound substrate at 
the domain interface. This mode of substrate binding has been referred to 
as the “venus fly trap mechanism”.8 SBPs can be divided into various groups 
using different classification schemes. Early classifications are mainly based on 
amino acid sequence information and knowledge of substrate specificity (i.e., 
metal-, carbohydrate-, vitamin-, tetrahedral oxyanions-, compatible solutes-, 
amino acids- and peptide-binding proteins).7 Alternatively, SBPs of known 
three-dimensional structure are commonly divided into three types, based on 
the central β-sheet topology of the two a/β domains and the architecture of 
the hinge region.9 A new structure-based classification, recently proposed by 
Berntsson et al.,10 further divides the three types into eight clusters, providing a 
more precise definition of the structural relationships among the different SBPs. 
In Gram-negative bacteria the majority of SBPs are located as soluble 
proteins in the periplasmic space (hence, this group of SBPs are also named 
periplasmic binding proteins), where they mainly associate with ATP-binding 
cassette (ABC)-transporters. As such they serve a central role in substrate 
translocation by binding their ligands selectively and delivering them to the 
translocation machinery in the membrane.2 Surprisingly, an SBP-like domain 
has also been reported to occur in a periplasmic protein not associated with 
solute transport, i.e. in the lytic transglycosylase family member MltF.11 Lytic 
transglycosylases (LTs) are specialized peptidoglycan-cleaving enzymes that 
have a role in cell wall remodeling and recycling during bacterial growth and 
cell division.12 They are ubiquitous among all eubacteria that produce PG, and 
are often present in several distinct forms within the same species.12-15 For 
Escherichia coli, MltF is the seventh LT family member that has been functionally 
characterized, and genomic sequence analysis show that it is also present in 




periplasmic enzyme that contains a typical lysozyme-like C-terminal domain 
responsible for its peptidoglycan degrading activity.16 Unlike all other LTs, 
however, it also contains an N-terminal domain homologous to the periplasmic 
SBPs of ABC transporters, in particular to those specific for histidine, lysine/
arginine/ornithine and glutamine. The function of this N-terminal domain 
(MltF-NTD) is unknown. 11  
To reveal its precise structural relationships with the SBPs and to find 
clues for unraveling its biological function, we set out to determine the three-
dimensional structure of MltF-NTD using X-ray crystallography. This study 
reports the crystal structure of MltF-NTD at 2.2 Å resolution.
eXPeRIMeNtAL PROCeDUReS
Structure determination
Expression, purification and crystallization of the soluble N-terminal domain 
of E. coli MltF (UniProt accession number P0AGC5), without the N-terminal 
signal sequence and carrying a C-terminal poly-histidine tag) has been 
published elsewhere.17 Initially, a partial structure of MltF-NTD was built in 
electron density maps at 3.0 Å resolution, obtained from Br-MAD diffraction 
experiments as described.17 This partial structure, which was only 52% 
complete, was then improved and extended using native diffraction data 
collected at 2.2 Å resolution. First, molecular replacement was carried out 
with the program Phaser.18 After obtaining a clear solution for the orientation 
and position of the partial structure in the asymmetric unit, the model was 
extended by automated model building using the program Resolve19 with data 
from 25 to 2.2 Å resolution. Ninety-three percent of the complete model was 
built automatically, and the remainder was added iteratively using manual 
building with the program Coot,20 alternated by restrained-model refinement 
using the programs Refmac5,21 and, in the final stages, Phenix.refine.22 For cross-
validation purposes using Rfree a randomly selected subset of reflections (5%) 
was left out from the refinements. TLS refinement was included in the final 
refinement runs.23 Water molecules were added using Coot based on stringent 
electron density and interaction geometry criteria. The final structure was 
refined to an Rwork and Rfree of 19.5% and 23.4%, respectively. Model assessment 
was carried out with Molprobity.24 Table 1 summarizes the refinement statistics.
Crystal structure of the N-terminal domain of MltF
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Sequence and structure analysis
Close homologs of E. coli MltF and multiple sequence alignments for sequence 
conservation analysis were obtained using BLAST, the JPRED server (http://




The structure of MltF-NTD (residues 23–270 of E. coli MltF, lacking the N-terminal 
signal peptide and including a C-terminal poly-histidine tag of sequence 
KLAAALEHHHHHH) was solved at 2.2 Å resolution by the multiple wavelength 
anomalous dispersion (MAD) technique using a bromide-soaked sMltF-NTD 
crystal. The crystallization procedure and diffraction data statistics were 
published elsewhere.17 Refinement details and model content are summarized 
in Table 1. The structure of MltF-NTD is well defined, except for the first eleven 
residues at the N-terminus (residues 23-33, sequence numbering is according 
to full length E. coli MltF with signal peptide) and the last seven residues of 
the poly-histidine tag. These regions appeared to be disordered and were 
therefore not included in the model.
Overall structure of MltF-NtD
MltF-NTD contains two a/β subdomains, that form a central groove at their 
interface and that are connected by a linker region that is composed of two 
β-strands (Figure 1). Subdomain S1, encompassing residues 34-124 and 229-
276, contains five a-helices (a1-a3, a7, a8) and two additional β-strands (β2-
β3) packed against a five-stranded mixed parallel/antiparallel β-sheet (β1, 
β4-β6, β14). The strand order of the β-sheet is β4-β1-β5-β14-β6, with β14 
following the crossover from subdomain S2 back to S1 and being the only 
anti-parallel β-strand in the sheet. Subdomain S2, encompassing residues 129-
226 has a similar five-stranded mixed parallel/antiparallel β-sheet (β8-β12), 




identical to that in S1, with β8 running anti-parallel with respect to the other 
strands and following the crossover from S1 to S2. The sheet topology of the 
two subdomains and the two β-strand subdomain linkers (β7 and β13) clearly 
define MltF-NTD as a type-2 SBP.9 A third β-strand (β15) interacts with the two 
β-strand linker, but this extra strand is formed by residues of the poly-histidine 
tag and thus represents an artificial extension of the protein domain. The MltF-
NTD structure contains no bound ligand at the inter-subdomain groove, and 
from the relative disposition of the two subdomains it is evident that it adopts 
an open conformation.
Comparison with other SBPs
A DALI search revealed a number of proteins with high structural similarity 
to MltF-NTD. Among the highest matches was the E. coli glutamine binding 
protein (GlnBP) [Z=19.5 with 209 of the 220 Ca atoms aligning with an RMSD 
Figure 1.
Overall structure of MltF-NtD. (A) Cartoon 
representation of the protein backbone with 
subdomains S1 and S2 colored in green and 
orange, respectively, and the two subdomain-
interconnecting strands colored in magenta. 
Secondary-structure elements were defined 
with the program DSSP (B) Topology diagram 
of MltF-NTD, using the same coloring scheme 
as in (A). 
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of 3.2 Å; PDB entry 1GGG],27 the Salmonella typhimurium LAO-binding protein 
(LAOBP) [Z=19.4 with 222 of the 238 Ca atoms aligning with an RMSD of 3.4 
Å; PDB entry 2LAO],28 and the E. coli histidine-binding protein (HisJ) [Z=16.8 
with 132 of 238 Ca atoms aligning with an RMSD of 2.1 Å; PDB entry 1HSL].29 
The identified proteins with high structural similarity also included a number 
of unpublished entries in the PDB, annotated as putative amino-acid-binding 
proteins of ABC transporters, and several eukaryotic ionotropic L-glutamate 
receptors and their bacterial homologs. All these close structural homologs 
are type-2 SBPs that belong to cluster F, following the recent classification by 
Berntsson et al.10 The sequence identity of MltF-NTD with these type-2 SBPs is 
low and ranges from 15-24 %. As expected, the overall structural similarity of 
MltF-NTD matches best the “open-unliganded” conformations of the SBPs, i.e. 
the “open-unliganded” structures of GlnBP and LAOBP are ranked significantly 
higher than their “closed-liganded” structures.27,28,30 The HisJ structure has only 
been determined in a “closed-liganded” conformation.29 The structure of MltF-
NTD, however, shows a more open conformation than most “open-unliganded” 
SBPs (Figure 2A). Compared to the “open” structures of GlnBP and LAOBP, the 
two subdomains in MltF-NTD are more widely apart and separated by an extra 
rotation of ~25-30 degrees.
The structural relationships become more apparent by analyzing 
individual structural superpositions of the subdomains of sMltF-NTD with the 
domains in the structures of GlnBP and LAOBP (“open-unliganded” and “closed-
liganded”) and HisJ (“closed-liganded”  (Figure 2B). The overall folds of S1 and 
S2 in sMltF-NTD are highly similar to those of their counterparts in the type 
2 amino-acid-binding proteins (RMSDs for the Ca-backbone overlays range 
from 1.9-2.5 Å), with significant differences being mainly confined to the N- and 
C-terminal regions. One pronounced difference is observed for the loop that 
connects β5 and β6 in S1 of sMltF-NTD (we named this segment the L3 loop, as 
explained below). Relative to the equivalent loops in the amino-acid-binding 
proteins, the L3 loop in MltF-NTD has shifted to a more outward position, 
away from the core of S1 towards the inter-subdomain cleft. The difference is 
remarkable, as the equivalent loop in the amino-acid-binding proteins has an 
important role in substrate binding and its conformation is highly conserved 
and relatively rigid, as judged from comparing the “open-unliganded” and 
“closed-liganded” structures of GlnBP and LAOBP. The conformational 




NTD, as will be further discussed below. A further difference is observed for 
the β-strand that forms the first inter-subdomain linker in sMltF-NTD (β7). 
This region in MltF-NTD is equivalent to that in GlnBP, but shorter than the 
corresponding linker regions in LAOBP and HisJ, which contain an insertion 
of five amino acid residues. The second interdomain linker (β13) in sMltF-NTD 
is similar to that in all three amino-acid-binding proteins. In SBPs the linker 
regions function as flexible hinges allowing the relative movement of the two 
domains as rigid-bodies. Unfortunately, we lack information that could signify 
whether sMltF-NTD exhibits a similar flexibility leading to a closure of its inter-
subdomain cleft. 
Characteristics of the potential substrate-binding site in MltF-NtD
While it is evident that the overall structure of MltF-NTD is closely related to 
type-2 periplasmic SBPs that bind polar and charged amino acid residues, the 
question remains whether this domain is also a functional SBP. Amino-acid 
binding proteins like GlnBP, LAOBP and HisJ recognize and bind their cognate 
ligands in a highly similar way and use a ligand binding pocket constructed 
from similar segments in the polypeptide chain.6,27-30 All type-2 amino-acid-
binding proteins use a conserved arginine residue (Arg75 in GlnBP, Arg77 in 
LAOBP, Arg77 in HisJ), threonine/serine residue (Thr70 in GlnBP, Ser72 in LAOBP, 
Ser72 in HisJ) and aspartate residue (Asp157 in GlnBP, Asp161 in LAOBP, Asp161 
in HisJ) to stabilize the a-ammonium and a-carboxyl groups of the amino acid 
ligands. The overall binding modes of the ligand side-chains are also similar, 
although the specific interactions are much more varied, as required to match 
differences in size, shape and charge. Hydrophobic interactions stabilize the 
stem of the side-chains, provided mainly by tyrosine, phenylalanine or leucine 
residues, while the head groups are stabilized via hydrogen bonding with 
specific protein residues and water molecules. In addition, in some of these 
SBPs the head group of their cognate ligand is stabilized via an interaction with 
a second conserved aspartate residue (Asp10 in GlnBP, Asp11 in LAOBP). To 
uncover whether MltF-NTD has a ligand-binding site we compared the ligand-
binding regions of LAOBP, GlnBP and HisJ with the structurally equivalent 
regions in MltF-NTD (Figure 3). Based on the overall structural similarity with 
the amino-acid-binding proteins six potential ligand-binding regions can be 
discerned in MltF-NTD (we named these regions L1-L6), which comprise loops 
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and termini of secondary structure elements that face the inter-subdomain cleft. 
Only two of these potential ligand-binding regions show a significant sequence 
identity with GlnBP, LAOBP, or HisJ. These are the aforementioned β6-β6 loop 
(L3) and the β11-a5 turn (L5), which in the amino-acid-binding proteins contain 
the conserved arginine, aspartate and threonine/serine residues that bind the 
a-ammonium and a-carboxyl groups of the amino acid ligand. However, only 
the arginine residue in the L3 loop and the aspartate residue in the L5 turn 
are conserved in MltF-NTD (Arg125 and Asp203), while the threonine/serine 
residue in the L3 loop is replaced by a valine residue (Val110). Furthermore, as 
already mentioned, the L3 loop adopts a significantly different conformation 
in MltF-NTD, and in the superposition with the “ligand-closed” structures of 
GlnBP, LAOBP and HisJ, it actually partially overlaps with the position of the 
bound ligands (Figure 4). In addition, the side chain of Arg115 in MltF-NTD 
Figure 2
Comparison of MltF-NtD with type-
2 amino-acid-binding proteins (A) 
Stereo diagram showing an overlay of 
the structure of MltF-NTD (dark blue) 
with the “open-unliganded” structure 
and “closed-liganded” structures of 
GlnBP (orange and yellow, respectively, 
PDB entries 1GGG and 1WDN)27,30. (B) 
Superpositions of subdomain S1 of 
MLtF-NTD (blue) on the equivalent 
domains of GlnBP (orange, “open-
unliganded”; yellow, Gln-bound) LAOBP 
(green, “open-unliganded”; yellow, Lys-
bound) and HisJ (red, His-bound) (C) 
Superpositions of subdomain S2 on the 





points away from the potential ligand site, a difference in conformation that is 
stabilized by a salt-bridge interaction between Arg115 and Asp95. Finally, the 
conformation of the L3 loop in MltF-NTD is incompatible with a full closure of 
the inter-subdomain cleft to form a closed MltF-NTD structure similar as the 
“ligand-closed” structures of the amino-acid-binding proteins, since the L3 
loop would clash with helix a5 of S2 at the subdomain interface. Thus, unless 
its L3 loop undergoes a dramatic conformational change upon ligand binding 
or upon closure of the inter-subdomain cleft, it seems unlikely that MltF-NTD 
binds similar amino acid ligands as GlnBP, LAOBP and HisJ. It is also possible, 
however, that MltF-NTD does not bind any ligand, and merely has a role as 
spacer-domain, to allow the C-terminal domain of the outer-membrane-bound 
protein to reach the peptidoglycan layer. Indeed, binding assays with different 
amino acid residues, small peptidoglycan-derived molecules, as well as isolated 
peptidoglycan have so far not been able to reveal a ligand-binding role for MltF-
NTD (our unpublished data). On the other hand, the residues in the potential 
ligand binding regions of MltF-NTD are highly conserved in MltF homologs 
from different bacterial species, strongly suggesting that these regions have a 
Figure 3
Structure-based multiple sequence 
alignment of MltF-NTD with GlnBP, 
LAOBP and HisJ. 
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functional role (Figure 5). Unfortunately, the current structural and functional 
data are insufficient to clarify whether MltF-NTD is functional SBP.
CONCLUSION
In this study, we have presented the crystal structure of the SBP-like N-terminal 
domain of MltF, a membrane-attached lytic transglycosylase from E. coli, at 
2.2 Å resolution. To the best of our knowledge, this is the first structure of an 
SBP that is present as a domain of an outer-membrane attached periplasmic 
protein. The structure of MltF-NTD displays close structural relationships with 
type-2 SBPs, in particular with the periplasmic SBPs of Gram-negative bacteria 
that participate in the binding and transport of polar and charged amino 
acid residues. In the crystal used to determine the structure of MltF-NTD the 
protein has an “open-unliganded” conformation, but it is unknown whether in 
solution the protein adopts different conformations, perhaps including those 
that more resemble a closed conformation. It is also unclear whether MltF-
Figure 4
Different conformation of the L3 loop in 
MltF-NTD. superposition of the L3 loop 
and L5 loop in MltF-NTD (blue) and Gln-
bound GlnBP (pink)
Figure 5 
Residue conservation in MltF-NtD. Surface 
representation of MltF-NTD, colored according to 
residue conservation as analyzed by the program 
Consurf. A total of 25 MltF proteins from different 
bacterial species were identified (cut-off of 50% 
sequence identity and used for the analysis of 
residue conservation. The colors vary from dark 





NTD has a ligand-binding function, but considering the differences in amino 
acid side chains and local backbone conformations at the inter-subdomain 
cleft, it seems unlikely that MltF-NTD binds similar amino acids as its SBP 
counterparts. Thus, the exact role of the N-terminal domain of MltF must await 
further biochemical and/or structural analysis. 
table 1: Summary of model refinement statistics
Space group P31 2 1
Cell dimensions
a, b, c (Å) 82.4, 82.4, 75.1 
a, β, γ (°) 90, 90, 120
Refinement
Resolution (Å) 25.4-2.2 Å
No. reflections 15184
Rwork / Rfree 0.19/0.23
No. atoms 1958
Protein (MltF-NTD monomer) 1896
 Water 62
B-factors (Å2)  
 Protein 58.3 Å2
 Ligand/ion -
 Water 52 Å2
r.m.s. deviations  
 Bond lengths (Å) 0.008
 Bond angles (°) 1.063
Ramachandran statistics of φ/ψ angles (%)
   Most favored
 
   Allowed
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Multidrug resistance (MDR) enables cells, such as bacterial and cancer cells, 
to withstand the toxicity of a variety of chemically different compounds. The 
emergence of MDR in disease-causing bacteria has resulted in the rise of 
superbugs, which have developed resistance to most available antibiotics. As 
a result the treatment of infectious diseases has become much more difficult 
as it necessitates the use of last-resort drugs and even then is sometimes 
unsuccessful. One of the main questions that remain largely unanswered is 
how the MDR strains identify all these different chemical compounds. Several 
types of resistance mechanisms have been identified, as discussed in Chapter 
1. Efflux pumps are membrane-bound transporters that have been proposed 
to be responsible for the identification and excretion of chemically different 
drugs preventing them from reaching their cellular targets. Very few structures 
of efflux pumps in the drug-bound form are available, and the structures that 
have been solved are of too low resolution to accurately depict and analyze 
the protein-drug interactions. 
MDR-like efflux pumps are ubiquitous in bacteria and have roles in 
many metabolic pathways. In a toxic environment (e.g. due to the presence 
of antibiotics) the expression of efflux pumps often increases to allow 
cell survival. Transcriptional regulators, which are DNA binding proteins, 
facilitate the up-regulation of the efflux pumps. In general, in the presence 
of toxic compounds, transcriptional regulators respond by binding to these 
compounds and enhancing the transcription of efflux pumps. For example, 
the well-characterized local transcriptional activator BmrR of Bacillus subtilis 
and the transcriptional repressor QacR of Staphylococcus aureus regulate the 
expression of the MDR efflux pumps Bmr and QacA, respectively. In order to 
perform their regulatory roles, MDR-related transcriptional regulators often 
exist as dimers. Each subunit comprises two domains, an N-terminal DNA-
binding domain and a C-terminal domain that is involved in dimerization and 
ligand binding. A helix-turn-helix motif located in the DNA binding domain 
facilitates DNA binding. Several families of MDR-related transcriptional 
regulators, such as TetR, MarR, MerR, AraC and PadR-like have been proposed 
based on commonalities in the DNA binding motif. The ligand binding domains, 
though they bind chemically similar ligands, vary structurally across the 
families and highlight the importance of studying the principles of multidrug 
specificity. Unlike the membrane-bound MDR transporters, transcriptional 
regulators are more accessible targets for structural- and drug-binding studies 
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as they can be easily expressed and purified in high amounts and are readily 
crystallizable. 
The Gram-positive bacterium Lactococcus lactis is a non-pathogenic 
bacterium that is widely used in the production of fermented foods. L. lactis 
has developed an MDR phenotype upon exposure to structurally unrelated 
compounds such as daunomycin, Hoechst 33342, ethidium and rhodamine 
6G. This MDR phenotype is due to the constitutive expression of lmrCD genes 
that encode an ATP-Binding Cassette (ABC) MDR transporter that excretes 
toxic compounds from the cell. The local transcriptional regulator LmrR 
regulates the expression of the lmrCD genes by responding to the same set of 
compounds as its cognate transporter LmrCD. By homology, LmrR belongs to 
PadR family of transcriptional regulators. 
Structures of several drug-bound forms of well-studied transcriptional 
regulators, like QacR and BmrR, have been obtained providing different insights 
into one of the most intriguing molecular aspects of MDR, namely multidrug 
recognition at atomic resolution, as summarized in Chapter 1. So far two 
different models exist to explain the phenomenon of multidrug recognition: 
a canonical “multisite” model, in which distinct overlapping minipockets and 
flexible elements present in a large single drug-binding site facilitate multidrug 
recognition. The second model suggests a smaller and single rigid drug-
binding pocket, composed of a hydrophobic slot for binding the common, 
aromatic cores of the target drugs, and a hydrophilic cavity for promiscuous 
binding of the variable drug constituents. Due to the varied nature of the drug-
binding sites several more examples are required for further advancement 
in understanding the principles of multidrug recognition. In the first part of 
this thesis (Chapters 2-3) we describe another unique model of multidrug 
recognition occurring in LmrR as deduced from X-ray crystallography. This 
technique allows us to probe the three-dimensional structures of proteins 
from which we can infer molecular details on how they function.
Multidrug recognition in LmrR
To understand the drug-binding features of LmrR, we solved crystal structures 
of this protein in a drug-free state at 2.0 Å resolution and of drug-bound forms 
of LmrR with Hoechst 33342 and daunomycin, both at 2.2 Å resolution. Similar 
116
Summary
to other MDR-related transcriptional regulators, LmrR executes its functions as 
a dimer. In the N-terminal DNA-binding domain, LmrR contains the canonical 
helix-turn-helix motif. A large central pore for drug binding, which is present 
at the dimer interface in LmrR, deviates from the drug-binding pockets of 
the previously studied QacR and BmrR regulators. The central pore in LmrR 
is symmetric with equal contributions from both monomers and has a pair 
of symmetry related tryptophan residues at the entrance. These features are 
unique because none of the MDR-related transcriptional regulators has a 
central pore at their dimer interface. The drug-binding sites of BmrR from B. 
subtilis and QacR from S. aureus are asymmetric and are located within a single 
subunit and contain several aromatic residues. In LmrR the planar ring system 
of the lipophilic drugs Hoechst 33342 and daunomycin is wedged between 
the side chains of the two tryptophans, having aromatic stacking interactions 
with their indole rings. There are no hydrogen bonding interactions between 
the drug(s) and LmrR. Binding of the drug in the central pore induces a change 
in the spacing between the DNA recognition helices. This change is postulated 
to prevent LmrR from binding to the control region of DNA resulting in the 
upregulation of the genes encoding the MDR transporter LmrCD. Thus by 
employing a pair of tryptophan residues in a single flexible drug-binding site, 
LmrR offers a novel mode of multidrug recognition, which deviates from the 
two models derived from the QacR and BmrR studies.
LmrR uses a single flexible drug-binding site for various drugs
In Chapter 3 we describe two additional drug-bound complexes of LmrR, with 
riboflavin (RBF) and ethidium (ET) at 2.4 Å and 2.0 Å resolution, respectively. The 
overall binding modes of RBF and ET are similar to those of Hoechst 33342 and 
daunomycin. Drug recognition is dominated by aromatic stacking interactions 
with the dimer-related tryptophan indole side chains. Furthermore, these 
complexes provide additional evidence that planar compounds with bulky 
hydrophilic side chains, like those of daunomycin and riboflavin, will have 
less binding affinity compared to those that have hydrophobic side chains, 
as present in ethidium. This is because hydrophilic side chains are less well 
accommodated within the hydrophobic binding site than the ethyl and phenyl 
side chains of ET. The two additional structures presented in this chapter 
confirm that LmrR uses a single drug-binding site within a large, symmetrical 
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and hydrophobic pore in the dimer interface, and that it deploys dimer-related 
tryptophan residues to accomplish multidrug recognition. 
As drug resistance is emerging at a faster rate than new antibiotics 
are discovered, there is an increasing need for the identification of new 
microbial drug targets. Lytic transglycosylases (LTs) may represent such a new 
interesting family of drug targets. These proteins are a set of autolysins found 
in peptidoglycan-containing eubacteria. Peptidoglycan (PG) is an important 
component of the cell wall of eubacteria. Its mesh-like structure allows the 
bacterial cells to withstand the high internal osmotic pressure.
LTs are glycosyl-transferases implicated in continuous remodeling and 
turnover of PG. Similar to lysozymes, LTs cleave the β-1,4 glycosidic linkage 
between N-acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc) 
residues present in peptidoglycan. However, unlike lysozymes, LTs also promote 
the formation of an intra-residue 1,6-glycosidic bond, producing GlcNAc-
anhydro-muropeptides. In Escherichia coli LTs are well studied. There are six 
outer membrane-bound (MltA, MltB, MltC, MltD, MltE, MltF) and one soluble 
lytic transglycosylase (Slt70). Most of the LTs contain additional non-catalytic 
domains for which the function is often unknown. Therefore, the specific roles 
of the different LTs in the PG metabolism of E. coli have remained unclear so far. 
Recently, it was reported that MltF contains an additional N-terminal domain 
that is homologous to periplasmic substrate-binding proteins (SBPs) of ABC 
transporters. The function of this N-terminal domain (MltF-NTD) is not known. 
efforts to understand the role of the N-terminal domain in the lytic 
transglycosylase MltF
In Chapter 4, crystallization experiments of a soluble form of the membrane-
bound lytic transglycosylase F from Escherichia coli (sMltF), and of its isolated 
N-terminal domain (sMltF-NTD), are reported together with an analysis of their 
3.5 Å and 2.2 Å resolution X-ray diffraction data. Initial attempts to elucidate 
the structures, using molecular replacement, of sMltF and sMltF-NTD were 
not successful. However, a three-wavelength MAD data set collected at 2.5 
Å resolution from bromide-soaked sMltF-NTD crystals enabled us to obtain 
phase information and subsequently allowed the building of a partial model. 
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Summary
Does sMltF-NtD have ligand-binding function?
The structure of sMltF-NTD is described in Chapter 5, confirming its 
relationships with periplasmic substrate binding proteins (SBPs), in particular 
those that are specific for glutamine, lysine/arginine/ornithine and histidine. 
The N-terminal domain of MltF contains two distinct subdomains connected 
by a hinge. MltF-NTD has an open conformation with a ligand-free inter-
subdomain cleft. In structures with a similar fold, the ligands are bound in the 
interdomain cleft. In those cases, a highly conserved arginine and aspartate 
residue in the cleft stabilize the a-ammonium and a-carboxylate groups of the 
ligands. Similarly, sMltF-NTD also contains such residues (Arg 125 and Asp203). 
However, the remaining residue composition of the interdomain cleft in sMltF 
differs from that of its structural homologues, and, possibly, these differences 
enable sMltF-NTD to have a different substrate specificity. For instance, MltF-
NTD may bind the reaction product delivered by its C-terminal lysozyme-
like catalytic domain, it could bind breakdown products of PG found in the 
periplasm, it may bind completely different compounds, or perhaps it even 
does not bind any ligand. These possibilities need to be tested further before a 
firm conclusion can be reached on the role and function of sMltF-NTD.
Using the structure of sMltF-NTD, new research can now be undertaken 
using experimental and computational methods to identify whether it has 
any role in ligand binding and subsequently in PG metabolism. Such methods 
may also allow us to determine whether sMltF-NTD can undergo a similar cleft 





Multidrug resistentie (MDR) geeft cellen, zoals bacterie- en kankercellen, de 
mogelijkheid om weerstand te bieden aan de toxiciteit van een groot scala 
aan chemisch diverse stoffen. Het ontstaan van MDR in ziekteverwekkende 
bacteriën heeft geleid tot de opmars van superbacteriën, die resistent zijn voor 
de meest gebruikte antibiotica. Om een infectie van deze MDR-bacteriën te 
behandelen wordt er gebruikt gemaakt van “laatste mogelijkheid” antibiotica 
en in enkele gevallen helpen deze ook niet. Hoe MDR-stammen de chemisch 
diverse stoffen kunnen herkennen en hoe ze de schadelijke effecten tegen 
gaan blijven open vragen. Een aantal verschillende resistentie-mechanismen 
zijn bekend, zoals beschreven in hoofdstuk 1. Efflux pompen zijn membraan 
gebonden transporters waarvan gedacht wordt dat ze chemisch diverse 
stoffen kunnen herkennen en uitscheiden voordat die stoffen schade aan de 
cel kunnen aanrichten. Een klein aantal kristalstructuren van efflux pompen 
met ligand zijn beschikbaar, maar de resolutie waarbij deze structuren zijn 
opgehelderd is veelal zo laag dat de interactie tussen eiwit en ligand niet goed 
bekeken en geanalyseerd kan worden.
MDR-achtige efflux pompen komen veel voor in bacteriën en hebben functies 
in verschillende metabole routes. Om in een giftige omgeving (bv. door de 
aanwezigheid van antibiotica) een grotere kans op overleven te hebben, 
verhogen cellen vaak de expressie van efflux pompen. Transcriptie regulatoren 
zijn DNA bindende eiwitten die de expressie van eiwitten reguleren door 
te reageren op omgevingsfactoren. In het geval van toxische stoffen zijn 
er transcriptie regulatoren die deze stoffen binden en zorgen voor een 
verhoogde transcriptie van efflux pompen. Enkele voorbeelden hiervan zijn 
de goed gekarakteriseerde transcriptie activator BmrR uit Bacillus subtilis en 
de transcriptie repressor QacR uit Staphylococcus aureus, die respectievelijk 
de expressie van de MDR efflux pompen Bmr en QacA reguleren. MDR-
gerelateerde transcriptie regulatoren komen vaak voor als dimeren, wat hun 
activiteit ten goede komt. Elke subunit bestaat uit twee domeinen, een DNA-
bindend domein en een C-terminaal domein die voor de dimerisatie en ligand 
binding zorgt. Het DNA-bindend domein heeft de bekende ‘helix-turn-helix’ 
vouwing en de klassificatie van verschillende MDR-gerelateerde transcriptie 
regulators in families, zoals TetR, MarR, MerR, AraC en PadR, is gebaseerd op 
overeenkomsten in aminozuurvolgorde van dit domein. Voor het ligand-
bindend domein geldt een ander verhaal. Deze is namelijk structureel heel 
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divers voor de verschillende MDR-gerelateerde transcriptie regulatoren, 
terwijl deze eiwitten vaak wel overeenkomstige liganden binden. Dit zijn dus 
interessante domeinen om de basis van multidrug specificiteit te bestuderen. 
In tegenstelling tot de membraangebonden MDR transporters zijn de 
transcriptie regulatoren voor structuur- en drugbindingsstudies makkelijker 
beschikbare targets, omdat de expressie en zuivering van de regulatoren 
eenvoudiger is en ze daarnaast makkelijker kristalliseren.
De Gram-positieve bacterie  Lactococcus lactis is niet pathogeen en wordt zeer 
veel gebruikt bij het produceren van gefermenteerd voedsel.  L. lactis heeft 
een MDR-fenotype als het blootgesteld wordt aan stoffen zoals daunomycine, 
Hoechst 33342, ethidium en rhodamine 6G, die alle chemisch gezien van 
elkaar verschillen. Dit fenotype ontstaat door de constante expressie van 
de zogenaamde lmrCD genen, die samen coderen voor een ATP-Bindende 
Cassette (ABC) MDR transporter. De locale transcriptie regulator LmrR reguleert 
de expressie van de lmrCD genen door te reageren op dezelfde set stoffen die 
de LmrCD transporter uit de cel pompt. Homologisch gezien behoort de LmrR 
tot de PadR familie van transcriptie regulatoren.
De structuren van drug-gebonden vormen van de transcriptie regulatoren, 
zoals QacR en BmrR, geven inzicht in één van de meer intrigerende moleculaire 
aspecten van MDR, namelijk hoe de chemisch verschillende stoffen herkend 
en gebonden worden op een atomair niveau (hoofdstuk 1). Tot op heden zijn 
er twee modellen die de herkenning van verschillende stoffen verklaren. Als 
eerste het ‘multi-site’ model, waarin gedefinieerde overlappende minipockets 
en flexibele elementen samen een grote drug-bindingsplaats vormen die 
multidrug herkenning mogelijk maakt. Het tweede model gaat uit van een 
kleinere en minder flexibele bindingsplaats, bestaande uit een hydrofobe 
gleuf waarin aromatische groepen van een target-drug kunnen binden, met 
daar omheen enkele hydrofiele holtes waarin de variabele groepen die aan de 
aromatische groep zitten terecht kunnen. Omdat er waarschijnlijk een grote 
variatie bestaat in drug-bindingsplaatsen, zijn er meer structuren nodig om 
een beter beeld te krijgen van multidrug herkenning. In het eerste deel van dit 
proefschrift (hoofdstukken 2 en 3) beschrijven we het model voor multidrug 
herkenning zoals dat voorkomt in LmrR, gebaseerd op kristallografische 
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data, en we tonen aan dat dit model significant verschilt van de twee eerder 
beschreven modellen.
Multidrug herkenning in LmrR
Om te begrijpen hoe LmrR drugs bindt, hebben we meerdere kristalstructuren 
opgehelderd. LmrR in ongebonden toestand is opgehelderd bij een resolutie 
van 2.0 Å, terwijl LmrR met Hoechst 33342 en daunomycine beide zijn 
opgehelderd bij een resolutie van 2.2 Å. Net als andere MDR transcriptie 
regulatoren moet ook LmrR dimeriseren om functioneel te zijn. Het 
N-terminale domein van LmrR heeft een ‘helix-turn-helix’ motief. Een grote 
en centrale drug-bindende porie, gelegen aan het dimeer raakvlak van LmrR, 
verschilt van de drug-bindende holtes van de QacR en BmrR regulatoren. De 
centrale porie in LmrR is symmetrisch en beide monomeren dragen evenveel 
bij aan deze porie. Verder zit er bij de ingang van de porie een symmetrie 
gerelateerd paar tryptofanen. Deze structuur eigenschappen komen niet 
voor bij de andere MDR-gerelateerde transcriptie regulatoren, wat LmrR uniek 
maakt. De drug bindende holtes van BmrR en QacR zijn asymmetrisch en 
liggen in een monomeer en bevatten verder meerdere aromatische residuen. 
In LmrR wordt het vlakke ringsysteem van Hoechst 33342 and daunomycine 
vast geklemd tussen de zijketens van de twee tryptofanen door middel van 
aromatische stacking. Er worden geen waterstofbruggen gevormd tussen de 
drugs en LmrR. Door de binding van een drug tussen de tryptofaan residuen 
ontstaat er een verandering in de afstand tussen de DNA bindende helices. 
Hoogstwaarschijnlijk kan LmrR hierdoor niet meer binden aan het DNA 
waardoor de genen coderend voor de MDR transporter LmrCD tot expressie 
worden gebracht. 
LmrR gebruikt een enkele drugbindingsplaats voor multidrug-binding
In hoofdstuk 3 beschrijven we nog twee structuren van LmrR in complex met 
een drug, namelijk met riboflavine (RBF), opgehelderd bij een resolutie van 2.4 
Å, en met ethidium (ET), opgehelderd bij 2.0 Å. RBF en ET worden gebonden, 
net als Hoechst 33342 en daunomycine, door middel van aromatische stacking 
met de indool groepen van de twee tryptofanen. Verder ondersteunen deze 
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twee nieuwe structuren het feit dat vlakke stoffen met hydrofiele zijketens, 
zoals daunomycine en RBF een lagere affiniteit voor LmrR hebben dan stoffen 
met hydrofobe zijketens, zoals ET. Dit komt voornamelijk doordat de hydrofiele 
zijketens minder goed passen in de hydrofobe bindingsplaats. De twee 
structuren uit dit hoofdstuk bevestigen dat LmrR maar één bindingsplaats 
gebruikt voor multidrug-herkenning en multidrug-binding
De huidige antibiotica worden in een steeds hoger tempo onbruikbaar door de 
opkomst van resistente microben. Er is daarom een grote noodzaak antibiotica 
te ontwikkelen die gericht zijn op nieuwe targets. Eén van deze targets zou de 
familie van lytische transglycosylases (LTs) kunnen zijn, die de peptidoglycaan 
laag (PG) in de celwand van bacteriën continu herstructureren. Het PG polymeer 
in de celwand zorgt ervoor dat bacteriën de hoge interne osmotische druk het 
hoofd kunnen bieden. De LTs verbreken, net als lysozym, de β-1,4-suikerbinding 
tussen N-acetylmuraminezuur (MurNAc) en N-acetylglucosamine (GlcNAc), 
die aanwezig zijn in het PG. Ze verschillen echter van lysozym omdat ze de 
vorming van een intra-residuele 1,6-suikerbinding katalyseren, wat resulteert 
in de vorming van GlcNAc-anhydro-muropeptides. De LTs uit Escherichia coli 
zijn goed bestudeerd; er zijn zes membraangebonden LTs (MltA, MltB, MltC, 
MltD, MltE, MltF) en één ongebonden LT (Slt70). De meeste LTs hebben, naast 
hun katalytische domein, één of meerdere andere domeinen waarvan de 
functie nog niet bekend is. Daarom zijn de specifieke rollen van deze E. coli 
LTs in het PG metabolisme nog onduidelijk. Uit een recente studie blijkt dat 
MltF een N-terminaal domein heeft dat homoloog is aan periplasmatische 
substraatbindende eiwitten (SBPs) van ABC transportereiwitten, maar de 
functie van dit N-terminale domein is echter niet bekend.
Pogingen om de rol van het N-terminale domein van de lytische 
transglycosylase MltF te begrijpen
In hoofdstuk 4 staat beschreven hoe een oplosbare vorm van MltF (sMltF), 
en zijn N-terminale domein (sMltF-NTD), zijn gekristalliseerd, en hoe deze 
kristallen zijn gebruikt voor röntgendiffractie experimenten. De diffractie 
van de sMltF kristallen had een maximaal oplossend vermogen van 3.5 Å en 
van de sMltF-NTD kristallen van 2.2 Å, maar pogingen om fase informatie te 
verkrijgen met behulp van de ‘molecular replacement’ methode wilden niet 
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lukken. Met behulp van een andere methode, namelijk “multiple-wavelength 
anomalous diffraction” en gebruikmakend van in een bromide oplossing 
gedrenkte kristallen, is het ons toch gelukt om de structuur op te helderen van 
sMltF-NTD.
heeft sMltF-NtD een ligandbindende functie?
De kristalstructuur van sMltF-NTD is beschreven in hoofdstuk 5 en hieruit kan 
opgemaakt worden dat er een duidelijke relatie is met SBPs, in het bijzonder met 
SBPs die specifiek zijn voor glutamine, lysine/arginine/ornithine en histidine. 
sMltF-NTD bestaat uit twee subdomeinen die met elkaar verbonden zijn door 
een scharnier. In de structuur heeft sMltF-NTD een open conformatie met een 
ligandloze groeve tussen de twee subdomeinen. In de gerelateerde SBPs zorgt 
de groeve voor de binding van een ligand. In dergelijke gevallen wordt het 
ligand gecoördineerd door een geconserveerde arginine en asparaginezuur 
residue. Deze residuen komen ook voor in het sMltF-NTD (Arg125 en Asp203), 
maar de meeste andere aminozuren in de groeve verschillen van die in de 
homologe SBPs. Deze verschillen zouden erop kunnen wijzen dat sMltF-NTD 
een andere substraatspecificiteit heeft, en bijvoorbeeld PG-gerelateerde 
liganden bindt zoals het reactieproduct van het C-terminale katalytische 
domein of afbraakproducten van PG die vrij voorkomen in het periplasma. 
Maar dit alles moet nog verder onderzocht worden voordat er conclusies 
getrokken kunnen worden.
Nu de kristalstructuur van sMltF-NTD bekend is, kunnen er nieuwe 
experimenten bedacht worden die mogelijk aantonen welke liganden dit 
domein kan binden en of zo’n ligandbindingsfunctie een rol speelt in het PG-
metabolisme. Verder zou het interessant zijn om te zien of sMltF-NTD, net als 
andere SBPs, open en dicht gaat als het een ligand bindt.
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